<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:22:07Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8530979" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8530979</identifier>
        <datestamp>2022-10-14</datestamp>
        <setSpec>clpt</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="cpt2408" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Clin Pharmacol Ther</journal-id>
              <journal-id journal-id-type="iso-abbrev">Clin Pharmacol Ther</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)1532-6535</journal-id>
              <journal-id journal-id-type="publisher-id">CPT</journal-id>
              <journal-title-group>
                <journal-title>Clinical Pharmacology and Therapeutics</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0009-9236</issn>
              <issn pub-type="epub">1532-6535</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8530979</article-id>
              <article-id pub-id-type="pmcid">PMC8530979</article-id>
              <article-id pub-id-type="pmc-uid">8530979</article-id>
              <article-id pub-id-type="pmid">34464454</article-id>
              <article-id pub-id-type="pmid">34464454</article-id>
              <article-id pub-id-type="doi">10.1002/cpt.2408</article-id>
              <article-id pub-id-type="publisher-id">CPT2408</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Articles</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment‐Resistant Epilepsy</article-title>
              </title-group>
              <contrib-group>
                <contrib id="cpt2408-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Davis</surname>
                    <given-names>Brittney H.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6717-2649</contrib-id>
                  <xref rid="cpt2408-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>brittneydavis@uabmc.edu</email>
                  </address>
                </contrib>
                <contrib id="cpt2408-cr-0002" contrib-type="author">
                  <name>
                    <surname>Beasley</surname>
                    <given-names>T. Mark</given-names>
                  </name>
                  <xref rid="cpt2408-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2408-cr-0003" contrib-type="author">
                  <name>
                    <surname>Amaral</surname>
                    <given-names>Michelle</given-names>
                  </name>
                  <xref rid="cpt2408-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2408-cr-0004" contrib-type="author">
                  <name>
                    <surname>Szaflarski</surname>
                    <given-names>Jerzy P.</given-names>
                  </name>
                  <xref rid="cpt2408-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2408-cr-0005" contrib-type="author">
                  <name>
                    <surname>Gaston</surname>
                    <given-names>Tyler</given-names>
                  </name>
                  <xref rid="cpt2408-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2408-cr-0006" contrib-type="author">
                  <name>
                    <surname>Perry Grayson</surname>
                    <given-names>Leslie</given-names>
                  </name>
                  <xref rid="cpt2408-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2408-cr-0007" contrib-type="author">
                  <name>
                    <surname>Standaert</surname>
                    <given-names>David G</given-names>
                  </name>
                  <xref rid="cpt2408-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="cpt2408-cr-0008" contrib-type="author">
                  <name>
                    <surname>Bebin</surname>
                    <given-names>E. Martina</given-names>
                  </name>
                  <xref rid="cpt2408-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="cpt2408-note-0001" ref-type="author-notes">
                    <sup>
                      <sup>1</sup>
                    </sup>
                  </xref>
                </contrib>
                <contrib id="cpt2408-cr-0009" contrib-type="author">
                  <name>
                    <surname>Limdi</surname>
                    <given-names>Nita A.</given-names>
                  </name>
                  <xref rid="cpt2408-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cpt2408-note-0001" ref-type="author-notes">
                    <sup>
                      <sup>1</sup>
                    </sup>
                  </xref>
                </contrib>
                <contrib id="cpt2408-cr-0010" contrib-type="author">
                  <collab collab-type="authors">the UAB CBD Study Group (includes all the investigators involved in the UAB EAP CBD program)</collab>
                </contrib>
              </contrib-group>
              <aff id="cpt2408-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Department of Neurology</named-content>
                <institution>University of Alabama at Birmingham</institution>
                <city>Birmingham</city>
                <named-content content-type="country-part">Alabama</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cpt2408-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Department of Biostatistics</named-content>
                <institution>University of Alabama at Birmingham</institution>
                <city>Birmingham</city>
                <named-content content-type="country-part">Alabama</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cpt2408-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <institution>HudsonAlpha Institute for Biotechnology</institution>
                <city>Huntsville</city>
                <named-content content-type="country-part">Alabama</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="cpt2408-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Department of Neurology</named-content>
                <institution>UAB Epilepsy Center</institution>
                <institution>University of Alabama at Birmingham</institution>
                <city>Birmingham</city>
                <named-content content-type="country-part">Alabama</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence: Brittney H. Davis (<email>brittneydavis@uabmc.edu</email>)<break/>
</corresp>
                <fn id="cpt2408-note-0001">
                  <label>
                    <sup>1</sup>
                  </label>
                  <p>Co‐senior authors.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>22</day>
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>22</day>
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <volume>110</volume>
              <issue seq="310">5</issue>
              <issue-id pub-id-type="doi">10.1002/cpt.v110.5</issue-id>
              <fpage>1368</fpage>
              <lpage>1380</lpage>
              <history>
                <date date-type="received">
                  <day>03</day>
                  <month>5</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>15</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2021 American Society for Clinical Pharmacology and Therapeutics-->
                <copyright-statement content-type="article-copyright">© 2021 The Authors. <italic toggle="yes">Clinical Pharmacology &amp; Therapeutics</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:CPT-110-1368.pdf"/>
              <abstract id="cpt2408-abs-0001">
                <p>In patients with treatment‐resistant epilepsy (TRE), cannabidiol (CBD) produces variable improvement in seizure control. Patients in the University of Alabama at Birmingham CBD Expanded Access Program (EAP) were enrolled in the genomic study and genotyped using the Affymetrix Drug Metabolizing Enzymes and Transporters plus array. Associations between variants and CBD response (≥50% seizure reduction) and tolerability (diarrhea, sedation, and abnormal liver function) was evaluated under dominant and recessive models. Expression quantitative trait loci (eQTL) influencing potential CBD targets was evaluated in the UK Brain Expression Consortium data set (Braineac), and genetic co‐expression examined. Of 169 EAP patients, 112 (54.5% pediatric and 50.0% female) were included in the genetic analyses. Patients with <italic toggle="yes">AOX1</italic> rs6729738 CC (aldehyde oxidase; odds ratio (OR) 6.69, 95% confidence interval (CI) 2.19–20.41, <italic toggle="yes">P</italic> = 0.001) or <italic toggle="yes">ABP1</italic> rs12539 (diamine oxidase; OR 3.96, 95% CI 1.62–9.73, <italic toggle="yes">P</italic> = 0.002) were more likely to respond. Conversely, patients with <italic toggle="yes">SLC15A1</italic> rs1339067 TT had lower odds of response (OR 0.06, 95% CI 0.01–0.56, <italic toggle="yes">P</italic> = 0.001). <italic toggle="yes">ABCC5</italic> rs3749442 was associated with lower likelihood of response and abnormal liver function tests, and higher likelihood of sedation. The eQTL revealed that rs1339067 decreased <italic toggle="yes">GPR18</italic> expression (endocannabinoid receptor) in white matter (<italic toggle="yes">P</italic> = 5.6 × 10<sup>−3</sup>), and rs3749442 decreased hippocampal <italic toggle="yes">HTR3E</italic> expression (serotonin 5‐HT<sub>3E</sub>; <italic toggle="yes">P</italic> = 8.5 × 10<sup>−5</sup>). Furthermore, 75% of genes associated with lower likelihood of response were co‐expressed. Pharmacogenetic variation is associated with CBD response and influences expression of CBD targets in TRE. Implicated pathways, including cholesterol metabolism and glutathione conjugation, demonstrate potential interactions between CBD and common medications (e.g., statins and acetaminophen) that may require closer monitoring. These results highlight the role of pharmacogenes in fundamental biologic processes and potential genetic underpinnings of treatment‐resistance.</p>
              </abstract>
              <counts>
                <fig-count count="4"/>
                <table-count count="3"/>
                <page-count count="13"/>
                <word-count count="8659"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>November 2021</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.0 mode:remove_FC converted:07.10.2022</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body id="cpt2408-body-0001">
            <p>
              <boxed-text position="anchor" content-type="box" id="cpt2408-blkfxd-0001">
                <caption>
                  <title>Study Highlights</title>
                </caption>
                <p>
                  <list list-type="simple" id="cpt2408-list-0001">
                    <list-item>
                      <p>
                        <bold>WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?</bold>
                      </p>
                    </list-item>
                  </list>
                </p>
                <p>☑ Cannabidiol (CBD) improves seizure control in patients with treatment‐resistant epilepsy (TRE); however, response remains highly variable. Genetic factors underlying this variability have not been evaluated.
<list list-type="simple" id="cpt2408-list-0002"><list-item><p><bold>WHAT QUESTION DID THIS STUDY ADDRESS?</bold></p></list-item></list>
</p>
                <p>☑ Do genetic factors influence CBD response (≥ 50% seizure reduction) and adverse effects in patients with TRE?
<list list-type="simple" id="cpt2408-list-0003"><list-item><p><bold>WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?</bold></p></list-item></list>
</p>
                <p>☑ Pharmacogenetic variation is associated with CBD response in TRE and influences expression of potential CBD targets, offering insight into potential mechanisms through which CBD exerts its therapeutic effects in TRE. Additionally, implicated pathways, such as cholesterol metabolism and glutathione conjugation, highlight the potential for interactions between CBD and common medications (e.g., statins, acetaminophen, etc.) that may require closer monitoring when co‐administered. Furthermore, genes associated with lower likelihood of response were largely co‐expressed.
<list list-type="simple" id="cpt2408-list-0004"><list-item><p><bold>HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?</bold></p></list-item></list>
</p>
                <p>☑ Understanding genetic mechanisms influencing CBD response in TRE can help identify patients who may benefit from treatment. Additionally, these results shed light on the role of pharmacogenes in fundamental biologic processes and potential genetic underpinnings of treatment‐resistance.</p>
              </boxed-text>
            </p>
            <sec sec-type="opening-section" id="cpt2408-sec-0002">
              <p>In the United States, approximately 3 million adults and 470,000 children have epilepsy.<xref rid="cpt2408-bib-0001" ref-type="bibr"><sup>1</sup></xref> Despite the availability of antiseizure drugs (ASDs) with varied mechanisms of action,<xref rid="cpt2408-bib-0002" ref-type="bibr"><sup>2</sup></xref> an estimated 25% of patients (15% children and 34% adults), have treatment‐resistant epilepsy (TRE), failing to achieve adequate seizure control despite treatment with ≥2 ASDs.<xref rid="cpt2408-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="cpt2408-bib-0004" ref-type="bibr"><sup>4</sup></xref> Additional therapies that can improve seizure control, mitigate disability, improve outcomes, and reduce costs are urgently needed.<xref rid="cpt2408-bib-0005" ref-type="bibr"><sup>5</sup></xref>
</p>
              <p>Cannabidiol (CBD) is a naturally occurring cannabinoid with antiseizure properties. Highly purified CBD (Epidiolex; Greenwich Biosciences Inc., Carlsbad, CA) is US Food and Drug Administration (FDA) approved for the treatment of seizures associated with Lennox‐Gastaut, Dravet syndromes, and tuberous sclerosis complex, in patients ≥ 1 year, and has recently demonstrated utility in other TREs.<xref rid="cpt2408-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="cpt2408-bib-0007" ref-type="bibr"><sup>7</sup></xref> However, CBD response remains highly variable, and the mechanisms underlying its therapeutic effects are not fully understood. CBD dose (mg/kg/day) directly related with higher CBD plasma levels (ng/mL), is associated with better seizure control.<xref rid="cpt2408-bib-0008" ref-type="bibr"><sup>8</sup></xref>
</p>
              <p>CBD is primarily metabolized by cytochrome P450 (CYP) CYP2C19 and CYP3A4, and the UDP‐glucuronosyltransferases (UGTs) UGT1A7, UGT1A9, and UGT2B7.<xref rid="cpt2408-bib-0009" ref-type="bibr"><sup>9</sup></xref> However, other CYPs, including CYP1A2, CYP2C9, and CYP2D6 are capable of metabolizing CBD.<xref rid="cpt2408-bib-0010" ref-type="bibr"><sup>10</sup></xref> Furthermore, CBD has the potential to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, UGT1A9, and UGT2B7.<xref rid="cpt2408-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="cpt2408-bib-0011" ref-type="bibr"><sup>11</sup></xref> The most common metabolites of CBD are 7‐COOH‐CBD, the inactive metabolite, 7‐OH‐CBD, the active metabolite, and the 6‐α‐OH‐CBD and 6‐β‐OH‐CBD minor metabolites.<xref rid="cpt2408-bib-0012" ref-type="bibr"><sup>12</sup></xref> However, CBD metabolism is complex, and over 40 phase I metabolites alone have been identified. The role of other drug metabolizing enzymes, such as those involved in glucuronide and sulfate conjugation, is still being elucidated.<xref rid="cpt2408-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="cpt2408-bib-0014" ref-type="bibr"><sup>14</sup></xref>
</p>
              <p>It is well recognized that genetic variation in pharmacogenes contributes to variability in drug response, ranging from lack of efficacy to susceptibility to adverse drug reactions.<xref rid="cpt2408-bib-0015" ref-type="bibr"><sup>15</sup></xref> Identification of genetic predictors of CBD response, both therapeutic and adverse, can help determine which patients could benefit from adjunct CBD treatment. Furthermore, given that many adverse drug effects occur as a result of interactions with target or off‐target tissues,<xref rid="cpt2408-bib-0016" ref-type="bibr"><sup>16</sup></xref> the identification of shared genetic predictors of response and adverse effects can offer insight into potential mechanisms underlying CBD action. To this end, we investigate the genetic underpinnings of therapeutic and adverse response in patients with TRE treated with CBD.</p>
            </sec>
            <sec sec-type="methods" id="cpt2408-sec-0003">
              <title>METHODS</title>
              <sec id="cpt2408-sec-0004">
                <title>Study population</title>
                <p>Patients were enrolled in a compassionate‐use open‐label CBD study for TRE with approval by the University of Alabama at Birmingham (UAB) Institutional Review Board as part of an Expanded Access Program (EAP; <ext-link xlink:href="http://www.clinicaltrials.gov" ext-link-type="uri">www.clinicaltrials.gov</ext-link>; NCT02695537 and NCT02700412).<xref rid="cpt2408-bib-0007" ref-type="bibr"><sup>7</sup></xref> All patients were Alabama residents with a TRE diagnosis confirmed by video electroencephalography monitoring; adequate trial/failure of ≥ 4 ASDs, including ≥ 1 trial of 2 concomitant ASDs; and an average of ≥ 4 seizures per month, averaged over 3 months. CBD was initiated at 5 mg/kg/day, administered in 2 divided doses, and titrated up in increments of 5 mg/kg/day every 2 weeks (up to 50 mg/kg/day) depending on tolerability and therapeutic response.</p>
              </sec>
              <sec id="cpt2408-sec-0005">
                <title>Pharmacogenomic study (May 2018–March 2019)</title>
                <p>An additional consent was obtained for the genomic study, and DNA samples collected when stable doses of CBD and concomitant ASDs were reached, with no changes for ≥ 2 weeks. Seizure frequencies/severity, concomitant ASDs, and laboratory data were documented at baseline and updated at each visit along with CBD dose and any adverse effects. All patients (or caregivers) were instructed to keep seizure diaries, which were verified during in‐person visits.</p>
              </sec>
              <sec id="cpt2408-sec-0006">
                <title>Genotyping and quality control</title>
                <p>Clinical Laboratory Improvement Amendment (CLIA)‐certified genotyping on the Affymetrix Drug Metabolizing Enzymes and Transporters plus array (1,931 variants/5 copy number regions across ~ 230 drug‐related genes)<xref rid="cpt2408-bib-0017" ref-type="bibr"><sup>17</sup></xref> was performed at the Coriell Institute for Medical Research (Camden, NJ) in two batches. Nine samples were re‐genotyped due to low call rates. Of the 1,931 variants, 1,328 were removed due to location on the X‐chromosome or a minor allele frequency &lt; 0.05. No variants were removed due to deviation from Hardy‐Weinberg equilibrium (<italic toggle="yes">P</italic> &lt; 0.0001). Variants in linkage disequilibrium (LD) were removed (<italic toggle="yes">n</italic> = 207, <italic toggle="yes">r</italic>
<sup>2</sup> = 0.5), leaving 396 variants. Due to the novel nature of the study, results including variants removed due to LD are presented in the <xref rid="cpt2408-sup-0001" ref-type="supplementary-material"><bold>Supporting Information</bold></xref>. Additionally, for variants associated with response, HaploReg was used to identify variants in LD (<italic toggle="yes">R</italic>
<sup>2</sup> = 0.8).<xref rid="cpt2408-bib-0018" ref-type="bibr"><sup>18</sup></xref> Call rates and variant frequencies are presented in <bold>Table </bold>
<xref rid="cpt2408-sup-0001" ref-type="supplementary-material"><bold>S1</bold></xref>.</p>
              </sec>
              <sec id="cpt2408-sec-0007">
                <title>Assessment of CBD response and tolerability</title>
                <p>As previously described, percent change in seizure frequency was determined at CBD stable dose, defined as the time/dose when each patient reached maximal seizure control, and calculated as ((seizure frequency per 28 days) – (seizure frequency at baseline))/(seizure frequency at baseline) × 100).<xref rid="cpt2408-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="cpt2408-bib-0008" ref-type="bibr"><sup>8</sup></xref> Response was categorized as no change/increase, &gt; 0 to 25%, ≥ 25% to &lt; 50%, ≥ 50% to &lt; 75%, and ≥ 75% reduction. Therapeutic response was defined as ≥ 50% reduction from baseline. Adverse effects were classified according to the Medical Dictionary for Regulatory Activities (MedDRA, version 17.1), and those that differed by response status (diarrhea, sedation, and abnormal liver function tests (LFTs)) were evaluated in the genetic analyses.</p>
              </sec>
              <sec id="cpt2408-sec-0008">
                <title>Statistical analyses</title>
                <p>After stratification by response status, differences in patient characteristics were assessed using analysis of variance models for continuous variables and <italic toggle="yes">χ</italic>
<sup>2</sup> tests for categorical variables. Due to concomitant ASD combinations, their limited influence on response,<xref rid="cpt2408-bib-0019" ref-type="bibr"><sup>19</sup></xref> and low interaction potential,<xref rid="cpt2408-bib-0020" ref-type="bibr"><sup>20</sup></xref> only ASDs expected to influence pharmacokinetic properties or have additive toxicity (e.g., clobazam sedation)<xref rid="cpt2408-bib-0021" ref-type="bibr"><sup>21</sup></xref> with CBD and used by ≥ 10% of patients were evaluated. This included clobazam, valproate, zonisamide, topiramate, and rufinamide. Eslicarbazepine (<italic toggle="yes">n</italic> = 5) and stiripentol (<italic toggle="yes">n</italic> = 0) were not included due to no/limited use. All statistical analyses were performed using PLINK (version 1.9) and SAS (version 9.4).</p>
                <p>The relationship between clinical predictors (dose, baseline weight, and concomitant ASDs) and CBD response/adverse effects was evaluated using logistic regression (<bold>Table </bold>
<xref rid="cpt2408-sup-0002" ref-type="supplementary-material"><bold>S2</bold></xref>). Genetic predictors of CBD response/adverse effects were evaluated using logistic regression under dominant (AA vs. Ab + bb) and recessive (AA + Ab vs. bb) models. Treatment‐group (adult/pediatric), race, and sex were included as covariates in clinical and genetic analyses. A permutation approach was used to account for multiple testing (number of permutations: 1,000), because other methods (e.g., Bonferroni correction) assume independence and would likely be overly conservative.<xref rid="cpt2408-bib-0022" ref-type="bibr"><sup>22</sup></xref> Given the exploratory nature of the study, <italic toggle="yes">P</italic> values &lt; 0.05 after permutation were considered significant. Additionally, for each outcome, a gene‐based correction was applied, based on the number of significant genes identified, to highlight impactful associations. For variants associated with response and an adverse effect, HaploReg was used to explore the influence of the variant on regulatory motifs.<xref rid="cpt2408-bib-0018" ref-type="bibr"><sup>18</sup></xref>
</p>
              </sec>
              <sec id="cpt2408-sec-0009">
                <title>Expression quantitative trait loci and co‐expression</title>
                <p>For response‐associated variants, we examined expression quantitative trait loci on potential CBD targets in epilepsy (e.g., G‐protein coupled receptors (GPCRs), voltage‐gated ion channels, etc.),<xref rid="cpt2408-bib-0023" ref-type="bibr"><sup>23</sup></xref> using the UK Brain Expression Consortium data set (Braineac)<xref rid="cpt2408-bib-0024" ref-type="bibr"><sup>24</sup></xref> and evaluated co‐expression using the co‐expression database, COEXPRESdb (version 7.3).<xref rid="cpt2408-bib-0025" ref-type="bibr"><sup>25</sup></xref> Promoter sequences of genes in the co‐expression network were obtained from Ensembl (GRCh37 Release 104), and homology evaluated using Basic Local Alignment Search Tool (BLAST). Sequences with an <italic toggle="yes">E</italic> value ≤ 1 × 10<sup>−50</sup> were considered high quality matches. PROMO (version 3.0.2),<xref rid="cpt2408-bib-0026" ref-type="bibr"><sup>26</sup></xref> was used to search for potential transcription factor binding sites shared among co‐expressed genes. The search was limited to sites with ≥ 95% similarity and present in all sequences.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="cpt2408-sec-0010">
              <title>RESULTS</title>
              <sec id="cpt2408-sec-0011">
                <title>Study population</title>
                <p>Of the 169 patients in the open‐label study,<xref rid="cpt2408-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="cpt2408-bib-0008" ref-type="bibr"><sup>8</sup></xref> 113 participated in the genomic study. One patient was excluded due to discordant sex, resulting in 112 patients (54.5% pediatric and 50.0% female) in the genetic analyses. Therapeutic response (≥ 50% seizure reduction) was achieved for 56.3% (63/112) patients at an average CBD dose of 26.6 2 ± 14.24 mg/kg/day. Clinical characteristics did not differ by response status (<bold>Table </bold>
<xref rid="cpt2408-tbl-0001" ref-type="table"><bold>1</bold></xref>), however, as previously reported,<xref rid="cpt2408-bib-0019" ref-type="bibr"><sup>19</sup></xref> responders received higher CBD doses. On average, patients had tried/failed eight ASDs and were on three concomitant ASDs. Diarrhea (<italic toggle="yes">P</italic> = 0.01) was more frequent in responders, whereas sedation (<italic toggle="yes">P</italic> = 0.05) was more common among nonresponders. The majority of patients (80.4%) experienced some degree of weight loss independent of therapeutic response.</p>
                <table-wrap position="float" id="cpt2408-tbl-0001" content-type="Table">
                  <label>Table 1</label>
                  <caption>
                    <p>Demographic and clinical characteristics between CBD responders and non‐responders</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <p>Overall</p>
                          <p>(<italic toggle="yes">N</italic> = 112)</p>
                        </th>
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <p>Responders</p>
                          <p>(<italic toggle="yes">N</italic> = 63)</p>
                        </th>
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <p>Non‐Responders</p>
                          <p>(<italic toggle="yes">N</italic> = 49)</p>
                        </th>
                        <th align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Demographics</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold><italic toggle="yes">N</italic> (%)</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold><italic toggle="yes">N</italic> (%)</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold><italic toggle="yes">N</italic> (%)</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Treatment Group</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Adult</td>
                        <td align="left" rowspan="1" colspan="1">51 (45.5%)</td>
                        <td align="left" rowspan="1" colspan="1">30 (47.6%)</td>
                        <td align="left" rowspan="1" colspan="1">21 (42.9%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.62</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Pediatric</td>
                        <td align="left" rowspan="1" colspan="1">61 (54.5%)</td>
                        <td align="left" rowspan="1" colspan="1">33 (52.4%)</td>
                        <td align="left" rowspan="1" colspan="1">28(57.1%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Gender</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td>
                        <td align="left" rowspan="1" colspan="1">56 (50.0%)</td>
                        <td align="left" rowspan="1" colspan="1">34 (54.0%)</td>
                        <td align="left" rowspan="1" colspan="1">22 (44.9%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.34</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td>
                        <td align="left" rowspan="1" colspan="1">56 (50.0%)</td>
                        <td align="left" rowspan="1" colspan="1">29 (46.0%)</td>
                        <td align="left" rowspan="1" colspan="1">27 (55.1%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Self‐reported race</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">African American</td>
                        <td align="left" rowspan="1" colspan="1">15 (13.4%)</td>
                        <td align="left" rowspan="1" colspan="1">10 (15.9%)</td>
                        <td align="left" rowspan="1" colspan="1">5 (10.2%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.65</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td>
                        <td align="left" rowspan="1" colspan="1">94 (83.9%)</td>
                        <td align="left" rowspan="1" colspan="1">52 (82.5%)</td>
                        <td align="left" rowspan="1" colspan="1">42 (85.7%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td>
                        <td align="left" rowspan="1" colspan="1">3 (0.03%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.02%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (0.04%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Baseline Characteristics</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Mean ± SD</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Mean ± SD</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Mean ± SD</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age</td>
                        <td align="left" rowspan="1" colspan="1">20.96 ± 16.11</td>
                        <td align="left" rowspan="1" colspan="1">19.76 ± 14.72</td>
                        <td align="left" rowspan="1" colspan="1">22.50 ± 17.77</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.39</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age at epilepsy onset</td>
                        <td align="left" rowspan="1" colspan="1">5.50 ± 9.82</td>
                        <td align="left" rowspan="1" colspan="1">5.37 ± 7.56</td>
                        <td align="left" rowspan="1" colspan="1">5.67 ± 12.22</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.88</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Weight (kg)</td>
                        <td align="left" rowspan="1" colspan="1">55.02 ± 28.88</td>
                        <td align="left" rowspan="1" colspan="1">55.70 ± 29.71</td>
                        <td align="left" rowspan="1" colspan="1">54.13 ± 28.07</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.77</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Bilirubin (mg/dl)</td>
                        <td align="left" rowspan="1" colspan="1">0.34 ± 0.16</td>
                        <td align="left" rowspan="1" colspan="1">0.32 ± 0.13</td>
                        <td align="left" rowspan="1" colspan="1">0.37 ± 0.19</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.13</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ALT</td>
                        <td align="left" rowspan="1" colspan="1">24.10 ± 12.06</td>
                        <td align="left" rowspan="1" colspan="1">24.03 ± 11.19</td>
                        <td align="left" rowspan="1" colspan="1">24.19 ± 13.17</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.95</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">AST</td>
                        <td align="left" rowspan="1" colspan="1">27.88 ± 14.53</td>
                        <td align="left" rowspan="1" colspan="1">27.41 ± 11.71</td>
                        <td align="left" rowspan="1" colspan="1">28.47 ± 17.54</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.72</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Seizure frequencies</td>
                        <td align="left" rowspan="1" colspan="1">136.26 ± 442.52</td>
                        <td align="left" rowspan="1" colspan="1">132.62 ± 407.24</td>
                        <td align="left" rowspan="1" colspan="1">140.94 ± 488.45</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.92</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">23.05 (6.36, 65.4)</td>
                        <td align="left" rowspan="1" colspan="1">29 (10, 68.7)</td>
                        <td align="left" rowspan="1" colspan="1">13.7 (5.2, 56.7)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.18</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ASDs tried/failed</td>
                        <td align="left" rowspan="1" colspan="1">8.32 ± 3.48</td>
                        <td align="left" rowspan="1" colspan="1">8.25 ± 3.35</td>
                        <td align="left" rowspan="1" colspan="1">8.41 ± 3.67</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.82</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Concomitant ASDs</td>
                        <td align="left" rowspan="1" colspan="1">2.64 ± 0.99</td>
                        <td align="left" rowspan="1" colspan="1">2.67 ± 1.03</td>
                        <td align="left" rowspan="1" colspan="1">2.61 ± 0.95</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.77</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Concomitant ASDs <italic toggle="yes">N</italic> (%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">clobazam</td>
                        <td align="left" rowspan="1" colspan="1">40 (35.7%)</td>
                        <td align="left" rowspan="1" colspan="1">21 (33.3%)</td>
                        <td align="left" rowspan="1" colspan="1">19 (38.8%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.55</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">valproate</td>
                        <td align="left" rowspan="1" colspan="1">21 (18.8%)</td>
                        <td align="left" rowspan="1" colspan="1">13 (20.6%)</td>
                        <td align="left" rowspan="1" colspan="1">8 (16.3%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.56</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">zonisamide</td>
                        <td align="left" rowspan="1" colspan="1">20 (17.9%)</td>
                        <td align="left" rowspan="1" colspan="1">13 (20.6%)</td>
                        <td align="left" rowspan="1" colspan="1">7 (14.3%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.38</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">topiramate</td>
                        <td align="left" rowspan="1" colspan="1">18 (16.1%)</td>
                        <td align="left" rowspan="1" colspan="1">10 (15.9%)</td>
                        <td align="left" rowspan="1" colspan="1">8 (16.3%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.95</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">rufinamide</td>
                        <td align="left" rowspan="1" colspan="1">12 (10.7%)</td>
                        <td align="left" rowspan="1" colspan="1">6 (9.5%)</td>
                        <td align="left" rowspan="1" colspan="1">6 (12.2%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.64</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Adverse Events*</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>N (%)</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>N (%)</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>N (%)</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diarrhea</td>
                        <td align="left" rowspan="1" colspan="1">66 (58.9%)</td>
                        <td align="left" rowspan="1" colspan="1">44 (69.8%)</td>
                        <td align="left" rowspan="1" colspan="1">22 (44.9%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.01</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Sedation</td>
                        <td align="left" rowspan="1" colspan="1">39 (34.8%)</td>
                        <td align="left" rowspan="1" colspan="1">17 (27.0%)</td>
                        <td align="left" rowspan="1" colspan="1">22 (44.9%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.05</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Nausea/vomiting</td>
                        <td align="left" rowspan="1" colspan="1">14 (12.5%)</td>
                        <td align="left" rowspan="1" colspan="1">9 (14.3%)</td>
                        <td align="left" rowspan="1" colspan="1">5 (10.2%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.52</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Abnormal liver function tests</td>
                        <td align="left" rowspan="1" colspan="1">12 (10.7%)</td>
                        <td align="left" rowspan="1" colspan="1">10 (15.9%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (4.1%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.05</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Weight Change</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">No Change or increase</td>
                        <td align="left" rowspan="1" colspan="1">22 (19.6%)</td>
                        <td align="left" rowspan="1" colspan="1">14 (22.2%)</td>
                        <td align="left" rowspan="1" colspan="1">8 (16.3%)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.67</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&lt;10% Weight loss</td>
                        <td align="left" rowspan="1" colspan="1">58 (51.8%)</td>
                        <td align="left" rowspan="1" colspan="1">32 (50.8%)</td>
                        <td align="left" rowspan="1" colspan="1">26 (53.1%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">10–20% Weight loss</td>
                        <td align="left" rowspan="1" colspan="1">23 (20.5%)</td>
                        <td align="left" rowspan="1" colspan="1">11 (17.5%)</td>
                        <td align="left" rowspan="1" colspan="1">12 (24.5%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">&gt;20% Weight loss</td>
                        <td align="left" rowspan="1" colspan="1">9 (8.0%)</td>
                        <td align="left" rowspan="1" colspan="1">6 (9.5%)</td>
                        <td align="left" rowspan="1" colspan="1">3 (6.1%)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Treatment‐Related Measures</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Mean ± SD</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Mean ± SD</bold>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Mean ± SD</bold>
                        </td>
                        <td align="char" char="." rowspan="1" colspan="1">
                          <bold><italic toggle="yes">p</italic>‐value</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">CBD dose (mg/kg/day)</td>
                        <td align="left" rowspan="1" colspan="1">23.81 ± 14.21</td>
                        <td align="left" rowspan="1" colspan="1">26.62 ± 14.24</td>
                        <td align="left" rowspan="1" colspan="1">20.20 ± 13.46</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.02</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Maintenance seizure frequency</td>
                        <td align="left" rowspan="1" colspan="1">58.54 ± 222.27</td>
                        <td align="left" rowspan="1" colspan="1">19.65 ± 46.09</td>
                        <td align="left" rowspan="1" colspan="1">108.52 ± 327.05</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.07</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">7.76 (2.58, 32.2)</td>
                        <td align="left" rowspan="1" colspan="1">4.50 (1.28, 13.6)</td>
                        <td align="left" rowspan="1" colspan="1">14.73 (5.67, 51)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Percent change seizure frequency</td>
                        <td align="left" rowspan="1" colspan="1">–42.08 ± 58.76</td>
                        <td align="left" rowspan="1" colspan="1">–79.20 ± 16.58</td>
                        <td align="left" rowspan="1" colspan="1">5.65 ± 59.13</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median (IQR)</td>
                        <td align="left" rowspan="1" colspan="1">–53.9 (–85.3, –17.1)</td>
                        <td align="left" rowspan="1" colspan="1">–82 (–94, –63.3)</td>
                        <td align="left" rowspan="1" colspan="1">–14.3 (–32.4, 2.7)</td>
                        <td align="char" char="." rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cpt2408-ntgp-0002">
                    <fn id="cpt2408-note-0010">
                      <p>Abbreviation: ASD, antiseizure drug.</p>
                    </fn>
                    <fn id="cpt2408-note-0020">
                      <p>*Other adverse effects included depressed mood (<italic toggle="yes">n</italic> = 12), decreased appetite (<italic toggle="yes">n</italic> = 12), rash (<italic toggle="yes">n</italic> = 11), upper respiratory infection (<italic toggle="yes">n</italic> = 8), hospital admission (<italic toggle="yes">n</italic> = 7), hyponatremia (<italic toggle="yes">n</italic> = 6), and abnormal CBC (<italic toggle="yes">n</italic> = 5).</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="cpt2408-sec-0012">
                <title>Genetic predictors of CBD response</title>
                <p>After accounting for treatment group, sex, race, and CBD dose, variation in <italic toggle="yes">AOX1</italic> (phase I aldehyde oxidase), <italic toggle="yes">SLC15A1</italic> (hydrogen peptide co‐transporter), and <italic toggle="yes">ABP1</italic> (<italic toggle="yes">AOC1</italic>, involved in histamine degradation)<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref> were associated with CBD response (<bold>Figure </bold>
<xref rid="cpt2408-fig-0001" ref-type="fig"><bold>1a</bold></xref>
<bold>;</bold>
<bold>Table </bold>
<xref rid="cpt2408-sup-0003" ref-type="supplementary-material"><bold>S3</bold></xref>). Patients with the <italic toggle="yes">AOX1</italic> rs6729738 CC genotype (odds ratio (OR) 6.69, 95% confidence interval (CI) 2.19–20.41, <italic toggle="yes">P</italic> = 0.001), and the <italic toggle="yes">ABP1</italic> rs12539 variant (OR 3.96, 95% CI 1.62–9.73, <italic toggle="yes">P</italic> = 0.002) were more likely to respond to CBD. Conversely, patients with the <italic toggle="yes">SLC15A1</italic> rs1339067 TT genotype had a 94% lower likelihood of response (OR 0.06, 95% CI 0.01–0.56, <italic toggle="yes">P</italic> = 0.001).</p>
                <fig position="float" fig-type="Figure" id="cpt2408-fig-0001">
                  <label>Figure 1</label>
                  <caption>
                    <p>Manhattan plots of (<bold>a</bold>) CBD response (≥ 50% seizure reduction) and CBD‐associated (<bold>b</bold>) diarrhea (<bold>c</bold>) sedation and (<bold>d</bold>) abnormal liver function tests. For all assessments, the blue line indicates a <italic toggle="yes">P</italic> value threshold of 0.05. <bold>a</bold> Genetic variants associated with CBD response adjusted for treatment group, race, sex, and CBD dose. Red line indicates a <italic toggle="yes">P</italic> value of 0.002 (0.05/29 significant genes). <bold>b</bold> Genetic variants associated with CBD‐related diarrhea after adjustment for treatment group, race, sex, baseline weight, and clobazam. Red line indicates a <italic toggle="yes">P</italic> value of 0.001 (0.05/36 significant genes). <bold>c</bold> Genetic variants associated with CBD‐associated sedation adjusted for treatment group, race, sex, CBD dose, clobazam, and rufinamide. Red line indicates a <italic toggle="yes">P</italic> value of 0.002 (0.05/27 significant genes). <bold>d</bold> Genetic variants associated with CBD‐associated abnormal liver function tests adjusted for treatment group, race, sex, and weight. Red line indicates a <italic toggle="yes">P</italic> value of 0.003 (0.05/18 significant genes). CBD, cannabidiol. [Colour figure can be viewed at <ext-link xlink:href="http://wileyonlinelibrary.com" ext-link-type="uri">wileyonlinelibrary.com</ext-link>]</p>
                  </caption>
                  <graphic xlink:href="CPT-110-1368-g003" position="anchor" id="jats-graphic-1"/>
                </fig>
                <p>With the exception of <italic toggle="yes">CYP17A1</italic> rs6162 (involved in steroid hormone biosynthesis),<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref> variation in CYP enzymes was associated with lower likelihood of response. Patients lacking <italic toggle="yes">CYP1A2</italic> rs762551 AA, associated with higher enzyme inducibility,<xref rid="cpt2408-bib-0028" ref-type="bibr"><sup>28</sup></xref> and those with <italic toggle="yes">CYP2D6</italic> rs28371725, had 56% (OR 0.44, 95% CI 0.19–0.98, <italic toggle="yes">P</italic> = 0.04) and 77% (OR 0.23, 95% CI 0.07–0.80, <italic toggle="yes">P</italic> = 0.02) lower odds of response, respectively. Similarly, patients with variation in the phase I flavin‐containing monooxygenases, <italic toggle="yes">FMO2</italic> rs7515157 TT (OR 0.18, 95% CI 0.04–0.82, <italic toggle="yes">P</italic> = 0.01), and <italic toggle="yes">FMO4</italic> rs2223477 G (OR 0.37, 95% CI 0.15–0.92, <italic toggle="yes">P</italic> = 0.04) were less likely to respond to CBD. Among phase I dehydrogenases, patients with homozygous variants in the alcohol dehydrogenase <italic toggle="yes">ADH4</italic> rs3762894 were less likely to respond to CBD (OR 0.10, 95% CI 0.01–0.92, <italic toggle="yes">P</italic> = 0.01); whereas patients with a dihydropyrimidine dehydrogenase (<italic toggle="yes">DPYD</italic>) rs1801265 variant had approximately threefold higher odds of response (OR 2.78, 95% CI 1.22–6.30, <italic toggle="yes">P</italic> = 0.02).</p>
                <p>Variants in phase II genes were primarily associated with higher likelihood of response. Patients with a carbohydrate sulfotransferase, <italic toggle="yes">CHST11</italic> rs903247 C allele (OR 3.93, 95% CI 1.68–9.19, <italic toggle="yes">P</italic> = 0.004), a <italic toggle="yes">UGT2B4</italic> rs1966151 C allele (OR 3.62, 95% CI 1.52–8.62, <italic toggle="yes">P</italic> = 0.004), or the <italic toggle="yes">SULT1A2</italic> rs1059491 CC genotype (OR 16.50, 95% CI 1.96–138.80, <italic toggle="yes">P</italic> = 0.005) were more likely to respond to CBD. Alternatively, patients with variants in glutathione‐S‐transferases (GSTs), including <italic toggle="yes">GSTM5</italic> rs2479390 (OR 0.33, 95% CI 0.14–0.79, <italic toggle="yes">P</italic> = 0.01) and <italic toggle="yes">GSTP1</italic> rs1695 CC (OR 0.12, 95% CI 0.02–0.65, <italic toggle="yes">P</italic> = 0.003) had a lower likelihood of response.</p>
                <p>Among transporters, patients with an <italic toggle="yes">ABCC4</italic> rs2274406 A allele (OR 3.08, 95% CI 1.29–7.37, <italic toggle="yes">P</italic> = 0.005) or an <italic toggle="yes">ABCG1</italic> rs914189 G allele (OR 2.64, 95% CI 1.09–6.39, <italic toggle="yes">P</italic> = 0.03) had a higher likelihood of response, whereas patients with <italic toggle="yes">ABCC5</italic> rs3749442 T had 64% lower odds of response (OR 0.36, 95% CI 0.15–0.85, <italic toggle="yes">P</italic> = 0.03). Variation in nuclear receptors was also found to be associated with CBD response. Patients with homozygous rs3814055 T variants in <italic toggle="yes">NR1I2</italic> (OR 0.35, 95% CI 0.12–0.99, <italic toggle="yes">P</italic> = 0.04), and those with a peroxisome proliferator activated receptor gamma (<italic toggle="yes">PPARγ</italic>) rs9833097 A allele (OR 0.34, 95% CI 0.12–0.92, <italic toggle="yes">P</italic> = 0.03) were less likely to respond to CBD. Variants in LD (<italic toggle="yes">R</italic>
<sup>2</sup> = 0.8) with response‐associated variants are presented in <bold>Table </bold>
<xref rid="cpt2408-sup-0004" ref-type="supplementary-material"><bold>S4</bold></xref>.</p>
              </sec>
              <sec id="cpt2408-sec-0013">
                <title>CBD‐associated diarrhea</title>
                <p>After accounting for treatment‐group, sex, race, weight, and clobazam, variation in phase I enzymes was associated with CBD‐related diarrhea (<bold>Figure </bold>
<xref rid="cpt2408-fig-0001" ref-type="fig"><bold>1b</bold></xref>
<bold>;</bold>
<bold>Table </bold>
<xref rid="cpt2408-sup-0005" ref-type="supplementary-material"><bold>S5</bold></xref>). Patients with the <italic toggle="yes">CYP2A6</italic> rs28399433 variant (OR 12.15, 95% CI 2.64–55.93, <italic toggle="yes">P</italic> = 0.001), involved in coumarin, nicotine, and caffeine metabolism,<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref> and those with the <italic toggle="yes">FMO6</italic> rs2272797 variant (OR 7.34, 95% CI 2.25–23.91, <italic toggle="yes">P</italic> = 0.001), encoding a pseudogene, were more likely to experience diarrhea.</p>
                <p>Additionally, patients with homozygous <italic toggle="yes">CYP39A1</italic> rs7761731 A alleles, involved in neural cholesterol clearance, had ninefold higher likelihood of CBD‐associated diarrhea (OR 9.03, 95% CI 1.34–60.65, <italic toggle="yes">P</italic> = 0.02). Among phase II pathways, patients with the rs9787901 variant in carbohydrate sulfotransferase (<italic toggle="yes">CHST1</italic>), were more likely to experience diarrhea (OR 4.80; 95% CI 1.24–18.55, <italic toggle="yes">P</italic> = 0.02); whereas patients with variation in pathways related to glutathione (<italic toggle="yes">GSTA3</italic> rs512795) and glucuronide conjugation (<italic toggle="yes">UGT2A1</italic> rs11249454) were less likely to experience diarrhea (<italic toggle="yes">P</italic> values &lt; 0.05). Patients with an <italic toggle="yes">ABCB11</italic> rs7563233 G allele or the rs496550 GG genotype, encoding the bile salt export pump, and patients with variants in <italic toggle="yes">SLCO1B3</italic> (rs3764006 and rs4149117), involved in bile acid clearance, were less likely to experience diarrhea (<italic toggle="yes">P</italic> values &lt; 0.05). <italic toggle="yes">ABCB1</italic> rs2214102, encoding P‐glycoprotein, and <italic toggle="yes">SLCO1B1</italic> rs11045819, encoding OATP1B1, were associated with higher (OR 3.54, 95% CI 1.13–11.13, <italic toggle="yes">P</italic> = 0.03), and lower (OR 0.28, 95% CI 0.08–0.98, <italic toggle="yes">P</italic> = 0.04) likelihood of diarrhea, respectively. Among variants associated with CBD response, <italic toggle="yes">ABP1</italic> rs12539, associated with higher odds of response, was also associated with higher likelihood of treatment‐related diarrhea (OR 3.25, 95% CI 1.20–8.85, <italic toggle="yes">P</italic> = 0.02). Alternatively, <italic toggle="yes">ABCC4</italic> rs2274406, associated with higher response under a dominant model, was associated with lower likelihood of diarrhea under a recessive model (OR 0.14, 95% CI 0.03–0.63, <italic toggle="yes">P</italic> = 0.01).</p>
              </sec>
              <sec id="cpt2408-sec-0014">
                <title>CBD‐associated sedation</title>
                <p>After accounting for treatment group, sex, race, CBD dose, clobazam, and rufinamide (<bold>Figure </bold>
<xref rid="cpt2408-fig-0001" ref-type="fig"><bold>1c</bold></xref>
<bold>;</bold>
<bold>Table </bold>
<xref rid="cpt2408-sup-0006" ref-type="supplementary-material"><bold>S6</bold></xref>), patients with homozygous <italic toggle="yes">ADH1A</italic> rs6811453 T alleles (OR 8.98, 95% CI 2.11–38.22, <italic toggle="yes">P</italic> = 0.002) or homozygous <italic toggle="yes">ABCG1</italic> rs1541290 G alleles (OR 6.71, 95% CI 2.15–20.92, <italic toggle="yes">P</italic> = 0.002) were more likely to experience sedation. Conversely, patients with the <italic toggle="yes">GSTM5</italic> rs11807 variant (phase II GST; OR 0.10, 95% CI 0.03–0.34, <italic toggle="yes">P</italic> = 0.002), or the <italic toggle="yes">SLC28A1</italic> rs8025045 variant (nucleoside transporter; OR 0.07, 95% CI 0.01–0.35, <italic toggle="yes">P</italic> = 0.002) were less likely to experience CBD‐associated sedation. Among variants associated with CBD response, patients with the <italic toggle="yes">ABCC5</italic> rs3749442 variant, associated with lower odds of response, were more likely to experience sedation (OR 3.51, 95% CI 1.42–8.66, <italic toggle="yes">P</italic> = 0.005). Alternatively, patients with the <italic toggle="yes">ABCG1</italic> rs914189 variant, associated with higher likelihood of response, had a 71% lower likelihood of sedation (OR 0.29, 95% CI 0.10–0.82, <italic toggle="yes">P</italic> = 0.02). Additionally, patients with <italic toggle="yes">CHST1</italic> rs9787901, associated with higher odds of diarrhea, had lower odds of sedation (OR 0.17, 95% CI 0.04–0.69, <italic toggle="yes">P</italic> = 0.01).</p>
              </sec>
              <sec id="cpt2408-sec-0015">
                <title>CBD‐associated abnormal LFTs</title>
                <p>After adjustment for treatment group, sex, race, and weight (<bold>Figure </bold>
<xref rid="cpt2408-fig-0001" ref-type="fig"><bold>1d</bold></xref>
<bold>;</bold>
<bold>Table </bold>
<xref rid="cpt2408-sup-0007" ref-type="supplementary-material"><bold>S7</bold></xref>), patients with the <italic toggle="yes">SULT1B1</italic> rs1604741 CC genotype had higher likelihood of developing abnormal LFTs (OR 8.49, 95% CI 1.77–40.77, <italic toggle="yes">P</italic> = 0.002). Patients with a <italic toggle="yes">SLC22A5</italic> rs274558 G allele, encoding a carnitine transporter, were less likely to develop abnormal LFTs (OR 0.11, 95% CI 0.02–0.53, <italic toggle="yes">P</italic> = 0.001).</p>
                <p>Patients with the apolipoprotein A2 (<italic toggle="yes">APOA2</italic>) rs5085 CC genotype (OR 7.00, 95% CI 1.20–41.16, <italic toggle="yes">P</italic> = 0.03) or a <italic toggle="yes">QPRT</italic> rs3862476 variant (involved in quinolinic acid degradation,<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref> OR 8.83, 95% CI 1.42–54.73, <italic toggle="yes">P</italic> = 0.02), were more likely to develop abnormal LFTs. Lower odds of abnormal LFTs were observed for patients with an <italic toggle="yes">ADH1A</italic> rs6811453 T allele (OR 0.20, 95% CI 0.04–0.93, <italic toggle="yes">P</italic> = 0.03) or a <italic toggle="yes">CYP39A1</italic> rs7761731 A allele (OR 0.17, 95% CI 0.03–0.91, <italic toggle="yes">P</italic> = 0.03), associated with higher odds of sedation and diarrhea, respectively, under recessive models. Valproic acid was not associated with abnormal LFTs (<italic toggle="yes">P</italic> = 0.56) and was not included as a covariate.</p>
              </sec>
              <sec id="cpt2408-sec-0016">
                <title>Shared genetic predictors of CBD response and adverse effects</title>
                <p>At the gene level, variation in pharmacogenes involved in phase I and II metabolism, drug transport, and other drug‐related processes, were associated with CBD response and adverse effects (<bold>Figure </bold>
<xref rid="cpt2408-fig-0002" ref-type="fig"><bold>2</bold></xref>). At the variant level, with the exception of <italic toggle="yes">SLC22A11</italic> rs2078267, all variants associated with CBD response and an adverse effect altered a regulatory motif (<bold>Table </bold>
<xref rid="cpt2408-tbl-0002" ref-type="table"><bold>2</bold></xref>). <italic toggle="yes">FMO4</italic> rs2223477, associated with lower odds of response and diarrhea, altered the Farnesoid x receptor motif, involved in bile acid synthesis and transport, and the RXRA motif. RXRA forms a heterodimer with PPARα, which is required for PPARα mediated activation of CYP genes and those involved in fatty acid oxidation.<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref>
<italic toggle="yes">ABP1</italic> rs12539, associated with increased odds of response and diarrhea, was found to influence the Cdx2 motif, involved in intestinal gene regulation, and Pax‐2, involved in central nervous system development and kidney cell differentiation.<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref>
</p>
                <fig position="float" fig-type="Figure" id="cpt2408-fig-0002">
                  <label>Figure 2</label>
                  <caption>
                    <p>Genes associated with CBD response (≥ 50% seizure reduction) and adverse effects based on permutation <italic toggle="yes">P</italic> values &lt; 0.05. For each gene, the variant with the smallest <italic toggle="yes">P</italic> value was used for each outcome. CBD, cannabidiol. [Colour figure can be viewed at <ext-link xlink:href="http://wileyonlinelibrary.com" ext-link-type="uri">wileyonlinelibrary.com</ext-link>]</p>
                  </caption>
                  <graphic xlink:href="CPT-110-1368-g004" position="anchor" id="jats-graphic-3"/>
                </fig>
                <table-wrap position="float" id="cpt2408-tbl-0002" content-type="Table">
                  <label>Table 2</label>
                  <caption>
                    <p>Influence of variants associated with CBD response and an adverse effect on regulatory motifs</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">
                          <p>
                            <italic toggle="yes">Gene</italic>
                          </p>
                          <p>variant</p>
                        </th>
                        <th align="left" valign="top" rowspan="1" colspan="1">CBD‐related outcome(s)</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Motif(s) altered</th>
                        <th align="left" valign="top" rowspan="1" colspan="1">Function<sup>27</sup>
</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <p>
                            <italic toggle="yes">FMO4</italic>
                          </p>
                          <p>rs2223477</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>Response (↓)</p>
                          <p>Diarrhea (↓)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">FXR (Farnesoid X Nuclear receptor)</td>
                        <td align="left" rowspan="1" colspan="1">Regulates genes involved in bile acid synthesis and transport</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Nrf1 (Nuclear Respiratory Factor 1)</td>
                        <td align="left" rowspan="1" colspan="1">Activates expression of metabolic and nuclear genes. May also regulate neurite outgrowth</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">RXRA (Retinoid X Receptor Alpha)</td>
                        <td align="left" rowspan="1" colspan="1">Mediates effects of retinoids. Forms heterodimer with PPARα, which is required for PPARα activation of genes involved in fatty acid oxidation and cytochrome P450 genes</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <p>
                            <italic toggle="yes">ABCC4</italic>
                          </p>
                          <p>rs2274406</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>Response (↑)</p>
                          <p>Diarrhea (↓)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">AP‐1 (Activator Protein 1)</td>
                        <td align="left" rowspan="1" colspan="1">Complex composed of members from Jun, Fos, ATF/cAMP‐responsive element binding and Maf families. Involved in cellular processes including inflammation, differentiation, and apoptosis</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">AP‐2 (Activating Enhancer‐Binding Protein 2)</td>
                        <td align="left" rowspan="1" colspan="1">Activates genes involved in biologic processes including proper development. Suppresses genes including C/EBP alpha</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <p>
                            <italic toggle="yes">ABCC5</italic>
                          </p>
                          <p>rs3749442</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>Response (↓)</p>
                          <p>Sedation (↑)</p>
                          <p>Abnormal LFTs (↓)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">Maf (MAF BZIP Transcription Factor)</td>
                        <td align="left" rowspan="1" colspan="1">Increases T‐cell apoptosis, activates G1 element of glucagon promoter, overexpression blocks anti‐oxidant response element mediated transcription</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Rad21 (RAD21 Cohesin Complex Component)</td>
                        <td align="left" rowspan="1" colspan="1">Member of the cohesin complex, required for proper chromosome organization and post‐replication DNA repair</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <p>
                            <italic toggle="yes">ABCG1</italic>
                          </p>
                          <p>rs914189</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>Response (↑)</p>
                          <p>Sedation (↓)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">AP‐1 (Activator Protein 1)</td>
                        <td align="left" rowspan="1" colspan="1">Complex composed of members from Jun, Fos, ATF/cAMP‐responsive element binding and Maf families. Involved in cellular processes including inflammation, differentiation, and apoptosis</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">SETDB1 (SET Domain Bifurcated Histone Lysine Methyltransferase 1)</td>
                        <td align="left" rowspan="1" colspan="1">Involved in the regulation of histone methylation, gene silencing and repressing transcription</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <p>
                            <italic toggle="yes">SLC22A11</italic>
                          </p>
                          <p>rs2078267</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>Response (↑)</p>
                          <p>Diarrhea (↑)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">NA</td>
                        <td align="left" rowspan="1" colspan="1">NA</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <p>
                            <italic toggle="yes">SLCO3A1</italic>
                          </p>
                          <p>rs2190748</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>Response (↓)</p>
                          <p>Diarrhea (↓)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">HNF4 (Hepatocyte Nuclear Factor 4)</td>
                        <td align="left" rowspan="1" colspan="1">Controls hepatic gene expression during endodermal transition to hepatic cells</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">SRF (Serum Response Factor)</td>
                        <td align="left" rowspan="1" colspan="1">Binds to serum response element and regulates cell cycle, growth and differentiation, and apoptosis. Downstream target of MAPK pathway</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <p>
                            <italic toggle="yes">SLCO4A1</italic>
                          </p>
                          <p>rs2236553</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>Response (↑)</p>
                          <p>Sedation (↓)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">TAL1 (TAL BHLH Transcription Factor 1, Erythroid Differentiation Factor)</td>
                        <td align="left" rowspan="1" colspan="1">Activates or represses transcription of hematopoietic, neural, and endothelial precursors</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <p>
                            <italic toggle="yes">ABP1</italic>
                          </p>
                          <p>rs12539</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">
                          <p>Response (↑)</p>
                          <p>Diarrhea (↑)</p>
                        </td>
                        <td align="left" rowspan="1" colspan="1">Cdx2 (Caudal Type Homeobox 2)</td>
                        <td align="left" rowspan="1" colspan="1">Regulator of intestinal genes involved in cell growth and differentiation</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">HNF1 (Hepatic Nuclear Factor 1)</td>
                        <td align="left" rowspan="1" colspan="1">Regulates many liver‐specific genes and pancreatic islet cells</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Pax‐2 (Paired Box Gene 2)</td>
                        <td align="left" rowspan="1" colspan="1">Critical role in CNS development, may also have role in kidney cell differentiation</td>
                      </tr>
                    </tbody>
                  </table>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
              </sec>
              <sec id="cpt2408-sec-0017">
                <title>Brain expression quantitative trait loci</title>
                <p>Variants associated with CBD response influenced the expression of GPCRs, serotonin receptors, tumor necrosis factor receptors, and voltage‐gated potassium channels in the brain (<bold>Table </bold>
<xref rid="cpt2408-tbl-0003" ref-type="table"><bold>3</bold></xref>). With the exception of VGKCs and <italic toggle="yes">GPR180</italic>, variants influencing the expression of potential CBD targets were primarily associated with lower likelihood of response. The rs3749442 A allele, associated with CBD response, sedation, and abnormal LFTs, was also associated with decreased hippocampal <italic toggle="yes">HTR3E</italic> (serotonin 5‐HT<sub>3E</sub> receptor) expression (<bold>Figure </bold>
<xref rid="cpt2408-fig-0003" ref-type="fig"><bold>3a</bold></xref>; <italic toggle="yes">P</italic> = 8.5 × 10<sup>−5</sup>). Additionally, rs1339067, associated with lower likelihood of CBD response under a recessive model (TT genotype), was associated with decreased <italic toggle="yes">GPR18</italic> expression (endocannabinoid receptor) in white matter (<bold>Figure </bold>
<xref rid="cpt2408-fig-0003" ref-type="fig"><bold>3b</bold></xref>; <italic toggle="yes">P</italic> = 5.6 × 10<sup>−3</sup>), and increased <italic toggle="yes">GPR183</italic> expression (oxysterol receptor) in the temporal cortex (<bold>Figure </bold>
<xref rid="cpt2408-fig-0003" ref-type="fig"><bold>3c</bold></xref>; <italic toggle="yes">P</italic> = 8.6 × 10<sup>−3</sup>).</p>
                <table-wrap position="float" id="cpt2408-tbl-0003" content-type="Table">
                  <label>Table 3</label>
                  <caption>
                    <p>Influence of CBD response‐associated variants on brain eQTL of potential CBD targets in epilepsy</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <col style="border-right:solid 1px #000000" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1">Variant</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">CBD‐related outcome(s)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Affected gene</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">
                          <p>eQTL</p>
                          <p><italic toggle="yes">P</italic> value</p>
                        </th>
                        <th align="center" valign="top" rowspan="1" colspan="1">eQTL tissue</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Function<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref>
</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="6" rowspan="1">
                          <italic toggle="yes">G protein coupled receptors (GPCRs)</italic>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="2" colspan="1">rs1339067</td>
                        <td align="center" rowspan="2" colspan="1">Response (↓)</td>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">GPR18</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">5.6 × 10<sup>−3</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">WHMT</td>
                        <td align="center" rowspan="1" colspan="1">
                          <p>Involved in inflammatory and immune responses, and the endocannabinoid system.</p>
                          <p>N‐arachidonoylglycine (anandamide metabolite) and resolvin D2 (polyunsaturated fatty acid metabolite) are proposed ligands.<xref rid="cpt2408-bib-0046" ref-type="bibr"><sup>46</sup></xref>
</p>
                        </td>
                      </tr>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">GPR183</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">8.6 × 10<sup>−3</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">TCTX</td>
                        <td align="center" rowspan="1" colspan="1">Oxysterol receptor expressed in lymphocytes. Involved in astrocyte migration and astrocyte‐macrophage communication. Ligands include 7‐alpha, 25‐dihydroxycholesterol.</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">rs2479390</td>
                        <td align="center" rowspan="1" colspan="1">Response (↓)</td>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">GPR61</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">4.4 × 10<sup>−4</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">CRBL</td>
                        <td align="center" rowspan="1" colspan="1">Orphan GPCR related to the biogenic amine receptor. Activates G(s)‐α/cAMP constitutively.</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">rs1695</td>
                        <td align="center" rowspan="1" colspan="1">Response (↓)</td>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">GPR152</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">2.8 × 10<sup>−2</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">WHMT</td>
                        <td align="center" rowspan="1" colspan="1">Ligands may include acetylcholine, serotonin, adrenaline, noradrenaline, dopamine, histamine, tyramine.<xref rid="cpt2408-bib-0049" ref-type="bibr"><sup>49</sup></xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">rs3814055</td>
                        <td align="center" rowspan="1" colspan="1">Response (↓)</td>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">GPR156</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">4.3 × 10<sup>−3</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">PUTM</td>
                        <td align="center" rowspan="1" colspan="1">Thought to be GABAB‐related G‐protein coupled receptor, but no response to GABAB ligands. Function unknown.<xref rid="cpt2408-bib-0050" ref-type="bibr"><sup>50</sup></xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">rs2274406</td>
                        <td align="center" rowspan="1" colspan="1">
                          <p>Response (↑)</p>
                          <p>Diarrhea (↓)</p>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">GPR180</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">2.7 × 10<sup>−2</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">TCTX</td>
                        <td align="center" rowspan="1" colspan="1">May play a role in vascular remodeling.</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="6" rowspan="1">
                          <italic toggle="yes">5‐Hydroxytryptamine receptors</italic>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">rs3749442</td>
                        <td align="center" rowspan="1" colspan="1">
                          <p>Response (↓)</p>
                          <p>Abnormal LFTs (↓)</p>
                          <p>Sedation (↑)</p>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">HTR3E</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">8.5 × 10<sup>−5</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">HIPP</td>
                        <td align="center" rowspan="1" colspan="1">Serotonin receptor subunit. May be involved in neurotransmission in myenteric neurons.</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="6" rowspan="1">
                          <italic toggle="yes">Tumor necrosis factor</italic>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">rs28371725</td>
                        <td align="center" rowspan="1" colspan="1">Response (↓)</td>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">TNFRSF13C</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">9.0 × 10<sup>−3</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">HIPP</td>
                        <td align="center" rowspan="1" colspan="1">Receptor for B‐cell activating factor (BAFF), involved in B‐cell regulation.</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="6" rowspan="1">
                          <italic toggle="yes">Voltage‐gated potassium channels</italic>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="4" colspan="1">rs2479390</td>
                        <td align="center" rowspan="4" colspan="1">Response (↓)</td>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">KCNC4</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">1.8 × 10<sup>−4</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">MEDU</td>
                        <td align="center" rowspan="1" colspan="1">Delayed rectifier potassium channel, mediates potassium permeability of excitable membranes.</td>
                      </tr>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">KCNA2</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">4.2 × 10<sup>−2</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">SNIG</td>
                        <td align="center" rowspan="1" colspan="1">Delayed rectifier potassium channel, which regulates neuronal output by preventing abnormal action potential firing.</td>
                      </tr>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">KCNA3</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">3.5 × 10<sup>−3</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">MEDU</td>
                        <td align="center" rowspan="1" colspan="1">Delayed rectifier potassium channel, mediates potassium permeability of excitable membranes. Also involved in T‐cell response.</td>
                      </tr>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">KCNA10</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">2.2 × 10<sup>−2</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">HIPP</td>
                        <td align="center" rowspan="1" colspan="1">Mediates potassium permeability of excitable membranes.</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">rs12539</td>
                        <td align="center" rowspan="1" colspan="1">
                          <p>Response (↑)</p>
                          <p>Diarrhea (↑)</p>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">KCNH2</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">3.5 × 10<sup>−4</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">FCTX</td>
                        <td align="center" rowspan="1" colspan="1">Forms subunit of voltage‐gated inward rectifying potassium channel.</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">rs2078267</td>
                        <td align="center" rowspan="1" colspan="1">
                          <p>Response (↑)</p>
                          <p>Diarrhea (↑)</p>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">KCNK4</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">2.8 × 10<sup>−3</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">MEDU</td>
                        <td align="center" rowspan="1" colspan="1">TWIK‐related arachidonic‐acid stimulated potassium channel. Forms voltage‐insensitive outward rectifying channel regulated by fatty acids, temperature, and mechanical stimulation.</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">rs2236553</td>
                        <td align="center" rowspan="1" colspan="1">
                          <p>Response (↑)</p>
                          <p>Sedation (↓)</p>
                        </td>
                        <td align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">KCNQ2</italic>
                        </td>
                        <td align="center" rowspan="1" colspan="1">9.3 × 10<sup>−3</sup>
</td>
                        <td align="center" rowspan="1" colspan="1">HIPP</td>
                        <td align="center" rowspan="1" colspan="1">Forms the M potassium channel upon association with KCNQ3. Plays critical role in neuronal excitability.</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="cpt2408-ntgp-0004">
                    <fn id="cpt2408-note-0006">
                      <p>eQTL tissues: WHMT, white matter; TCTX, temporal cortex; CRBL, cerebellar cortex; PUTM, putamen; HIPP, hippocampus; MEDU, medulla; FCTX, frontal cortex; SNIG, Substantia nigra.</p>
                    </fn>
                    <fn id="cpt2408-note-0007">
                      <p>Other potential CBD targets evaluated, but not identified, included adenosine receptors, transient receptor potential cation channels (TRP), voltage gated ion channels (calcium, sodium), and voltage dependent anion channel.</p>
                    </fn>
                    <fn id="cpt2408-note-0008">
                      <p>CBD, cannabidiol; eQTL, expression quantitative trait loci.</p>
                    </fn>
                  </table-wrap-foot>
                  <permissions>
                    <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                  </permissions>
                </table-wrap>
                <fig position="float" fig-type="Figure" id="cpt2408-fig-0003">
                  <label>Figure 3</label>
                  <caption>
                    <p>Expression of genes encoding potential CBD targets stratified by response‐associated variants. (<bold>a</bold>) <italic toggle="yes">HTR3E</italic> expression stratified by rs3749442. (<bold>b</bold>) <italic toggle="yes">GPR18</italic> expression stratified by rs1339067. (<bold>c</bold>) GPR183 expression stratified by rs1339067. CBD, cannabidiol; eQTL, expression quantitative trait loci. [Colour figure can be viewed at <ext-link xlink:href="http://wileyonlinelibrary.com" ext-link-type="uri">wileyonlinelibrary.com</ext-link>]</p>
                  </caption>
                  <graphic xlink:href="CPT-110-1368-g001" position="anchor" id="jats-graphic-5"/>
                </fig>
              </sec>
              <sec id="cpt2408-sec-0018">
                <title>Genetic co‐expression, sequence homology, and epistasis</title>
                <p>Among CBD response‐related genes (16 lower and 13 higher), 58.6% (17/29) were identified in the co‐expression network (<bold>Figure </bold>
<xref rid="cpt2408-fig-0004" ref-type="fig"><bold>4</bold></xref>). Notably, 75% (12/16) of genes associated with lower likelihood of response were co‐expressed, whereas only 38.5% (5/13) of genes associated with higher likelihood of response were co‐expressed. Pathways represented in the co‐expression network included retinoic acid and MAPK pathways. Additionally, <italic toggle="yes">NOTCH2NL</italic>, involved in the regulation of genes involved in neuronal differentiation, was co‐expressed with <italic toggle="yes">GSTP1</italic> and <italic toggle="yes">SLC22A5</italic>, both associated with lower odds of CBD response.</p>
                <fig position="float" fig-type="Figure" id="cpt2408-fig-0004">
                  <label>Figure 4</label>
                  <caption>
                    <p>Co‐expression network among CBD response associated genes. Genes associated with CBD response are outlined in black. Colored circles indicate blue: phase I metabolism, green: phase II metabolism, coral: SLC family transporters, pink: ABC family transporters, yellow: other drug‐related genes, and black: other genes. CBD, cannabidiol.</p>
                  </caption>
                  <graphic xlink:href="CPT-110-1368-g002" position="anchor" id="jats-graphic-7"/>
                </fig>
                <p>Among shared promoter sequences of genes in the co‐expression network, <italic toggle="yes">PDZD3</italic> and <italic toggle="yes">SLC9A3R1</italic> shared 90.6% (<italic toggle="yes">E</italic> value 1 × 10<sup>−135</sup>) and 91.3% (<italic toggle="yes">E</italic> value 4.7 × 10<sup>−75</sup>) alignment with <italic toggle="yes">DLG2</italic>, involved in the regulation of NMDA receptors and synaptic stability.<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref> Similarly, <italic toggle="yes">PDZD3</italic> and <italic toggle="yes">SLC9AR1</italic> shared 85.4% (<italic toggle="yes">E</italic> value 1.3 × 10<sup>−114</sup>) and 86.6% (<italic toggle="yes">E</italic> value 5.3 × 10<sup>−61</sup>) alignment, respectively, with <italic toggle="yes">NRG3</italic> (neuregulin 3), an ERBB4 ligand potentially involved in oligodendrocyte survival. <italic toggle="yes">ERC1</italic>, encoding an RIM‐binding protein, involved in the regulation of neurotransmitter release,<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref> shared 91.0% alignment with <italic toggle="yes">GSTP1</italic> (<italic toggle="yes">E</italic> value 1.7 × 10<sup>−57</sup>), associated with lower odds of response, and 88.8% alignment with <italic toggle="yes">SLC9A3R2</italic> (<italic toggle="yes">E</italic> value 4.5 × 10<sup>−84</sup>). Furthermore, <italic toggle="yes">SLC35F2</italic>, whose transcripts are enriched in brain microvascular endothelial cells forming the blood brain barrier,<xref rid="cpt2408-bib-0029" ref-type="bibr"><sup>29</sup></xref> shared 88.9% alignment with <italic toggle="yes">PDZD3</italic> (<italic toggle="yes">E</italic> value 2.2 × 10<sup>−130</sup>) and 91.5% alignment with <italic toggle="yes">SLC9A3R2</italic> (<italic toggle="yes">E</italic> value 2.3 × 10<sup>−59</sup>).</p>
                <p>When the promoter sequences of genes in the co‐expression network were evaluated for potential shared transcription factor binding sites, CEBPβ (CCAAT/enhancer binding protein beta), GR‐β (glucocorticoid receptor beta), and STAT4 (signal transducer and activator of transcription 4) sites were present (≥ 95% similarity) in all promoter sequences of genes in the co‐expression network. Notably, <italic toggle="yes">AOX1</italic> rs6729738, the most significant variant associated with response, alters the <italic toggle="yes">NR3C1</italic> motif,<xref rid="cpt2408-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="cpt2408-bib-0030" ref-type="bibr"><sup>30</sup></xref> encoding the glucocorticoid receptor (GR).</p>
                <p>When epistasis was evaluated, an interaction was observed between <italic toggle="yes">UGT2B4</italic> rs1966151, associated with higher odds of response, and rs1152003 in the nuclear receptor, <italic toggle="yes">PPARγ</italic> (<italic toggle="yes">P</italic> = 1.46 × 10<sup>−5</sup>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="cpt2408-sec-0019">
              <title>DISCUSSION</title>
              <p>Our study highlights the effect of genetic variation on both seizure reduction and susceptibility to adverse effects in patients with TRE treated with CBD. Concordant with previous studies, our results support complex CBD metabolism, with genetic variation across pharmacogenes implicated in response and tolerability. Additionally, our results demonstrate that genes associated with CBD response may influence the expression of potential CBD targets in epilepsy, and that genes associated with lower likelihood of therapeutic response appear to be largely co‐expressed. Pharmacogenes influence fundamental biologic processes independent of their role in drug metabolism/transport and can shed light on potential mechanisms that may contribute to pathologic processes, such as TRE. The analysis highlights the influence of pharmacogenes on interconnected pathways related to cholesterol, bile acids, steroid hormones, purine and pyrimidine metabolism, proteoglycans and neuroprotection, and free radical generation and scavenging. This complex interplay allows us to identify potential interactions with commonly used medications (e.g., statins and acetaminophen) that may influence CBD efficacy and/or tolerability.</p>
              <p><italic toggle="yes">AOX1</italic> and <italic toggle="yes">DPYD</italic> were associated with response. <italic toggle="yes">AOX1</italic>, involved in retinaldehyde, benzaldehyde, and vanillin metabolism, can catalyze the formation of hydrogen peroxide and superoxide.<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref> CBD has been shown to decrease reactive oxygen species,<xref rid="cpt2408-bib-0031" ref-type="bibr"><sup>31</sup></xref> a potential explanation of its therapeutic effect in TRE. Additionally, <italic toggle="yes">AOX1</italic> and <italic toggle="yes">DPYD</italic> are associated with impaired purine and pyrimidine metabolism,<xref rid="cpt2408-bib-0032" ref-type="bibr"><sup>32</sup></xref> and have been implicated in amyotrophic lateral sclerosis (<italic toggle="yes">AOX1</italic>),<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref> and epilepsy (DPYD). DPYD is also responsible for the metabolism of fluoropyrimidines (fluorouracil and capecitabine).<xref rid="cpt2408-bib-0033" ref-type="bibr"><sup>33</sup></xref> Although DPYD‐mediated response may be due to underlying biologic process, and not CBD metabolism, additional monitoring may be required if fluoropyrimidines and CBD are co‐administered.</p>
              <p>Variants in CHSTs were associated with response (<italic toggle="yes">CHST11</italic>), and diarrhea and sedation (<italic toggle="yes">CHST1</italic>). CHST11 and CHST1 sulfate chondroitin and keratan sulfate proteoglycans, respectively. Both are important components of the brain extracellular matrix, and help form perineuronal nets, which are vital to neuroprotection, neuronal development, and plasticity.<xref rid="cpt2408-bib-0034" ref-type="bibr"><sup>34</sup></xref>, <xref rid="cpt2408-bib-0035" ref-type="bibr"><sup>35</sup></xref> Additionally, CHST1 has been shown to play a role in inflammatory responses.<xref rid="cpt2408-bib-0036" ref-type="bibr"><sup>36</sup></xref> Remodeling of chondroitin sulfate proteoglycans has been implicated in neurologic conditions, including epilepsy and Alzheimer’s disease.<xref rid="cpt2408-bib-0037" ref-type="bibr"><sup>37</sup></xref> Given that variation in <italic toggle="yes">CHSTs</italic> was identified across CBD‐related outcomes, carbohydrate‐dependent mechanisms may contribute to CBD response and tolerability in TRE.</p>
              <p>Variants in GSTs were associated with lower response (<italic toggle="yes">GSTM5</italic> and <italic toggle="yes">GSTP1</italic>), abnormal LFTs (<italic toggle="yes">GSTM2</italic>), diarrhea (<italic toggle="yes">GSTA3</italic>), and sedation (<italic toggle="yes">GSTM3</italic> and <italic toggle="yes">GSTM5</italic>). Glutathione is an antioxidant and free radical scavenger, with deficiency implicated in neurodegenerative conditions, including epilepsy, Alzheimer’s disease, and multiple sclerosis.<xref rid="cpt2408-bib-0038" ref-type="bibr"><sup>38</sup></xref> CBD has been shown to increase glutathione activity, thereby decreasing oxidative stress.<xref rid="cpt2408-bib-0039" ref-type="bibr"><sup>39</sup></xref> Although it is not clear if glutathione depletion contributes to CBD resistance, or if variation in <italic toggle="yes">GSTM5</italic> and <italic toggle="yes">GSTP1</italic> impair CBD‐mediated increases in glutathione activity, glutathione‐dependent pathways appear to play a role in CBD response and tolerability. Saturability of the glutathione conjugation pathway highlights the need to monitor patients on co‐therapy with drugs (e.g., acetaminophen) that utilize this pathway.</p>
              <p>Genes involved in cholesterol and bile acid‐associated pathways were identified across CBD‐related outcomes and altered bile acid signaling has been implicated in epilepsy development.<xref rid="cpt2408-bib-0040" ref-type="bibr"><sup>40</sup></xref> Genes involved in neural cholesterol conversion to bile acids (<italic toggle="yes">CYP39A1</italic>), bile acid conjugation (<italic toggle="yes">UGT2B4</italic>) and transport (<italic toggle="yes">ABCB11</italic>, <italic toggle="yes">ABCB4</italic>, <italic toggle="yes">SLCO1B1</italic>, and <italic toggle="yes">SLCO1B3</italic>), and apolipoprotein A2 (<italic toggle="yes">APOA2</italic>), were associated with CBD response and adverse effects. Additionally, <italic toggle="yes">FMO4</italic> rs2223477, associated with lower odds of response and diarrhea, affected the Farnesoid x receptor motif, involved in the regulation of genes involved in bile acid synthesis and transport.<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref>
<italic toggle="yes">ABCG1</italic> rs914189, involved in phospholipid export (sphingomyelin, cholesterol, and oxysterols)<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref> has previously been associated with high‐density lipoprotein cholesterol levels.<xref rid="cpt2408-bib-0041" ref-type="bibr"><sup>41</sup></xref> Furthermore, <italic toggle="yes">SLCO1B1</italic> rs11045819 A, encoding OATP1B1, involved in the transport of numerous endogenous substances and statin drugs, was associated with diarrhea. This variant is associated with increased fluvastatin efficacy, as measured by low‐density lipoprotein cholesterol reduction.<xref rid="cpt2408-bib-0042" ref-type="bibr"><sup>42</sup></xref> Given the potential CBD‐statin interaction, monitoring of LFTs in patients on CBD‐statin co‐therapy should be considered.</p>
              <p>Steroid hormone pathways were also implicated in CBD response and tolerability. In addition to bile acid conjugation, UGT2B4 is active on catechol estrogens, or endogenous estrogen metabolites. Catechol estrogens modulate calcium influx and insulin secretion through activation of the transient receptor potential (TRP) A1 channel,<xref rid="cpt2408-bib-0043" ref-type="bibr"><sup>43</sup></xref> and CBD has activity at TRP channels, specifically TRPV1.<xref rid="cpt2408-bib-0023" ref-type="bibr"><sup>23</sup></xref>
<italic toggle="yes">CYP17A1</italic> rs6162, associated with higher odds of response, was previously associated with higher androstenedione levels, the precursor to estrone and testosterone.<xref rid="cpt2408-bib-0044" ref-type="bibr"><sup>44</sup></xref>
<italic toggle="yes">AOX1</italic> rs6729738, associated with response, influenced the GR motif, and GR‐β was identified in the promoter sequences of all co‐expressed genes. GR‐β does not bind glucocorticoids or activate glucocorticoid responsive genes, but antagonizes the effects of GR‐α, thereby inhibiting glucocorticoid effects.<xref rid="cpt2408-bib-0045" ref-type="bibr"><sup>45</sup></xref> Given that patients with homozygous <italic toggle="yes">AOX1</italic> rs6729738 reference C alleles had higher odds of response, GR alteration may contribute to therapeutic response to CBD. Additionally, apart from drug metabolism, CYP1A2 is involved in cholesterol and caffeine metabolism, and the conversion of estrone to catecholestrogens.<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref> Given that lower ability to induce CYP1A2 was associated with lower odds of response, CYP1A2 induction may contribute to response in TRE. However, it is not clear if this is due to CYP1A2‐mediated CBD metabolism or underlying biologic processes. CYP1A2 activity is influenced by factors including smoking, diet, caffeine intake, and drugs (proton‐pump inhibitors, oral contraceptives, antibiotics, and antidepressants),<xref rid="cpt2408-bib-0028" ref-type="bibr"><sup>28</sup></xref> and these factors may influence CBD response in TRE. The involvement of steroid hormone‐related pathways indicates that CBD response may be dependent on sex and age. We plan to assess these influences in larger CBD‐treated TRE cohorts.</p>
              <p>Among variants associated with CBD response, we identified variants influencing the expression of GPCRs, tumor necrosis factor receptors, serotonin receptors, VGKCs, and PPARγ. Variation in <italic toggle="yes">PPARγ</italic> was associated with lower odds of response and was involved in a significant interaction with <italic toggle="yes">UGT2B4</italic>. Furthermore, CEBP β, whose transcription factor binding site was identified in the promoter sequences of all genes in the co‐expression network, induces CEBPα and <italic toggle="yes">PPARγ</italic> upon phosphorylation. <italic toggle="yes">PPARγ</italic> is highly expressed in adipose tissue and is involved in glucose metabolism and lipid storage.<xref rid="cpt2408-bib-0027" ref-type="bibr"><sup>27</sup></xref> Given that ~ 80% of patients experienced some degree of weight loss, <italic toggle="yes">PPARγ</italic>‐mediated mechanisms influencing <italic toggle="yes">UGT2B4</italic> may contribute to CBD response. Additionally, we found that rs1339067, associated with lower odds of response, decreased the expression of the GPR18 endocannabinoid receptor. GPR18 shares some similarities with the GPR55 cannabinoid receptor, and both bind ligands that are not active at the CB<sub>1</sub>R and CB<sub>2</sub>R cannabinoid receptors.<xref rid="cpt2408-bib-0046" ref-type="bibr"><sup>46</sup></xref>
<italic toggle="yes">N</italic>‐arachidonyl glycine (NAGly), a metabolite of the endogenous cannabinoid anandamide, serves as the ligand for GPR18; however, the role of NAGly at GPR18 is not fully understood. We also found that rs3749442, associated with response and adverse effects, was associated with decreased expression of <italic toggle="yes">HTR3E</italic>, encoding the serotonin 5‐HT<sub>3E</sub> receptor. The 5‐HT<sub>3E</sub> receptor requires co‐expression with 5‐HT<sub>3A</sub> to form a functional receptor, and serotonin has been shown to have increased activity at 5‐HT<sub>3A/E</sub>.<xref rid="cpt2408-bib-0047" ref-type="bibr"><sup>47</sup></xref> Although not much is known about the pharmacology of the 5‐HT<sub>3A/E</sub> receptor,<xref rid="cpt2408-bib-0048" ref-type="bibr"><sup>48</sup></xref> it may play a role in modulating CBD response in TRE.</p>
              <p>Although exquisitely phenotyped, we recognize limitations, including limited sample size, numerous ASD combinations, and the inability to assess response based on seizure subtypes. Additionally, data on concomitant medications and environmental factors (e.g., smoking, caffeine intake, and diet) was not available, so these influences could not be evaluated. Whereas we did not identify variants in <italic toggle="yes">CYP2C19</italic> associated with response, rs3758581 a component on numerous <italic toggle="yes">CYP2C19</italic> star alleles was associated with lower likelihood of sedation and higher likelihood of developing abnormal LFTs. However, this variant is also in complete LD with the <italic toggle="yes">CYP2C9*3</italic> (rs1057910) decreased function allele. Although CYP2C19 is a major CBD metabolic pathway, given the number of identified metabolites,<xref rid="cpt2408-bib-0013" ref-type="bibr"><sup>13</sup></xref> non‐CYP2C19 dependent pathways may contribute to CBD effects and require further evaluation (i.e., aldehyde oxidase and flavin‐containing monooxygenases). Furthermore, because CBD dose was titrated based on response and adverse effects, this may have negated the effects of <italic toggle="yes">CYP2C19</italic> genetic variation.</p>
              <p>Genetic variation in pharmacogenes is associated with CBD response and the development of adverse effects in TRE. Furthermore, variation in these genes influences the expression of potential CBD targets. Our study demonstrates that pharmacogenes implicated in CBD response are also involved in fundamental biologic processes and may offer novel insight into mechanisms through which CBD exerts its therapeutic effects in TRE and potential genetic underpinnings of treatment‐resistance. Additionally, as many of these pathways are associated with other neurodegenerative diseases, CBD’s therapeutic potential for neurodegenerative diseases needs further evaluation.</p>
            </sec>
            <sec id="cpt2408-sec-0020">
              <title>FUNDING</title>
              <p>This work was supported by the Alabama Cannabinoid Program and in part by National Institutes of Health (NIH) grants (K24HL133373 (N.A.L.) and T32HG008961 (B.H.D.)). GW Research Ltd. provided Epidiolex for the study.</p>
            </sec>
            <sec sec-type="COI-statement" id="cpt2408-sec-0021">
              <title>CONFLICT OF INTEREST</title>
              <p>In the past 2 years, E.M.B. received funding from the NIH, State of Alabama, Greenwich Biosciences; has served on consulting/advisory boards for Greenwich Biosciences, Springworks Therapeutics, Inc., Neurelis, Aquestive Therapeutics, and REGENXBIO; and editorial board member for Pediatric Neurology Journal. In the last 2 years, J.P.S. received funding from the NIH, National Science Foundation, US Department of Defense, State of Alabama, Shor Foundation for Epilepsy Research, UCB Pharma, NeuroPace, Greenwich Biosciences, Biogen, Xenon Pharmaceuticals, and Serina Therapeutics; has served on consulting/advisory boards for Greenwich Biosciences, NeuroPace, Serina Therapeutics, LivaNova, UCB Pharma, and iFovea; and has served as an editorial board member for <italic toggle="yes">Epilepsy &amp; Behavior</italic>, <italic toggle="yes">Journal of Epileptology</italic> (Associate Editor), <italic toggle="yes">Epilepsy &amp; Behavior Reports</italic> (Associate Editor), <italic toggle="yes">Journal of Medical Science</italic>, <italic toggle="yes">Epilepsy Currents</italic> (Contributing Editor), and <italic toggle="yes">Folia Medica Copernicana</italic>. J.P.S. is a member of the faculty of the University of Alabama at Birmingham and is supported by endowment and University funds. J.P.S. is an investigator in studies funded by Abbvie, Inc., the American Parkinson Disease Association, the Michael J. Fox Foundation for Parkinson Research, Alabama Department of Commerce, the Department of Defense, and NIH grants P50NS108675, R25NS079188, and T32NS095775. He has a clinical practice and is compensated for these activities through the University of Alabama Health Services Foundation. In addition, since January 1, 2020, he has served as a consultant for or received honoraria from Abbvie Inc., Sutter Health, the International Parkinson Disease and Movement Disorder Society, Theravance, McGraw Hill, and Sanofi‐Aventis. In the last 2 years, T.G. has received consulting fees from Greenwich Biosciences, WebMD/MedScape, and Versar, Inc. All other authors declared no competing interests for this work.</p>
            </sec>
            <sec id="cpt2408-sec-0022">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p>All authors wrote the manuscript. B.H.D., E.M.B., and N.A.L. designed the research. B.H.D., E.M.B., and N.A.L. performed the research. B.H.D., M.B., M.A., E.M.B., and N.A.L. analyzed the data.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="cpt2408-sup-0001" position="float" content-type="local-data">
                <caption>
                  <p>Table S1</p>
                </caption>
                <media xlink:href="CPT-110-1368-s003.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cpt2408-sup-0002" position="float" content-type="local-data">
                <caption>
                  <p>Table S2</p>
                </caption>
                <media xlink:href="CPT-110-1368-s002.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cpt2408-sup-0003" position="float" content-type="local-data">
                <caption>
                  <p>Table S3</p>
                </caption>
                <media xlink:href="CPT-110-1368-s006.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cpt2408-sup-0004" position="float" content-type="local-data">
                <caption>
                  <p>Table S4</p>
                </caption>
                <media xlink:href="CPT-110-1368-s007.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cpt2408-sup-0005" position="float" content-type="local-data">
                <caption>
                  <p>Table S5</p>
                </caption>
                <media xlink:href="CPT-110-1368-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cpt2408-sup-0006" position="float" content-type="local-data">
                <caption>
                  <p>Table S6</p>
                </caption>
                <media xlink:href="CPT-110-1368-s005.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="cpt2408-sup-0007" position="float" content-type="local-data">
                <caption>
                  <p>Table S7</p>
                </caption>
                <media xlink:href="CPT-110-1368-s004.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ref-list content-type="cited-references" id="cpt2408-bibl-0001">
              <title> </title>
              <ref id="cpt2408-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0001"><string-name><surname>Zack</surname>, <given-names>M.M.</given-names></string-name> &amp; <string-name><surname>Kobau</surname>, <given-names>R.</given-names></string-name>
<article-title>National and state estimates of the numbers of adults and children with active epilepsy ‐ United States, 2015</article-title>. <source>MMWR Morb. Mortal Wkly. Rep.</source>
<volume>66</volume>, <fpage>821</fpage>–<lpage>825</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28796763</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0002"><string-name><surname>Vossler</surname>, <given-names>D.G.</given-names></string-name>, <string-name><surname>Weingarten</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Gidal</surname>, <given-names>B.E.</given-names></string-name> &amp; <collab collab-type="authors">American Epilepsy Society Treatments Committee</collab>
. <article-title>Summary of antiepileptic drugs available in the United States of America: working toward a world without epilepsy</article-title>. <source>Epilepsy Curr.</source>
<volume>18</volume>, <fpage>1</fpage>–<lpage>26</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30233275</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0003"><string-name><surname>Kalilani</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Pelgrims</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Noack‐Rink</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Villanueva</surname>, <given-names>V.</given-names></string-name>
<article-title>The epidemiology of drug‐resistant epilepsy: a systematic review and meta‐analysis</article-title>. <source>Epilepsia</source>
<volume>59</volume>, <fpage>2179</fpage>–<lpage>2193</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30426482</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0004"><string-name><surname>Kwan</surname>, <given-names>P.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies</article-title>. <source>Epilepsia</source><volume>51</volume>, <fpage>1069</fpage>–<lpage>1077</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">19889013</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0005"><string-name><surname>Sheikh</surname>, <given-names>S.R.</given-names></string-name>, <string-name><surname>Thompson</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Frech</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Malhotra</surname>, <given-names>M.</given-names></string-name> &amp; <string-name><surname>Jehi</surname>, <given-names>L.</given-names></string-name>
<article-title>Quantifying the burden of generalized tonic‐clonic seizures in patients with drug‐resistant epilepsy</article-title>. <source>Epilepsia</source>
<volume>61</volume>, <fpage>1627</fpage>–<lpage>1637</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32658343</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0006"><string-name><surname>Szaflarski</surname>, <given-names>J.P.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results</article-title>. <source>Epilepsia</source><volume>59</volume>, <fpage>1540</fpage>–<lpage>1548</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29998598</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0007"><string-name><surname>Szaflarski</surname>, <given-names>J.P.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open‐label add‐on prospective study</article-title>. <source>Epilepsy Behav.</source><volume>87</volume>, <fpage>131</fpage>–<lpage>136</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30100226</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0008"><string-name><surname>Szaflarski</surname>, <given-names>J.P.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol</article-title>. <source>Epilepsy Behav.</source><volume>95</volume>, <fpage>131</fpage>–<lpage>136</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31048098</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="book" id="cpt2408-cit-0009"><source>Epidiolex [package insert]</source> (<publisher-name>Greenwich Biosciences, Inc.</publisher-name>, <publisher-loc>Carlsbad, CA</publisher-loc>, <year>2020</year>).</mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0010"><string-name><surname>Jiang</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Yamaori</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Takeda</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Yamamoto</surname>, <given-names>I.</given-names></string-name> &amp; <string-name><surname>Watanabe</surname>, <given-names>K.</given-names></string-name>
<article-title>Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes</article-title>. <source>Life Sci.</source>
<volume>89</volume>, <fpage>165</fpage>–<lpage>170</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21704641</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0011"><string-name><surname>Yamaori</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Okamoto</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Yamamoto</surname>, <given-names>I.</given-names></string-name> &amp; <string-name><surname>Watanabe</surname>, <given-names>K.</given-names></string-name>
<article-title>Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6</article-title>. <source>Drug Metab. Dispos.</source>
<volume>39</volume>, <fpage>2049</fpage>–<lpage>2056</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21821735</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0012"><string-name><surname>Pérez‐Acevedo</surname>, <given-names>A.P.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Disposition of cannabidiol metabolites in serum and urine from healthy individuals treated with pharmaceutical preparations of medical cannabis</article-title>. <source>Pharmaceuticals (Basel)</source><volume>13</volume>, <fpage>459</fpage> (<year>2020</year>).</mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0013"><string-name><surname>Ujváry</surname>, <given-names>I.</given-names></string-name> &amp; <string-name><surname>Hanuš</surname>, <given-names>L.</given-names></string-name>
<article-title>Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy</article-title>. <source>Cannabis Cannabinoid Res.</source>
<volume>1</volume>, <fpage>90</fpage>–<lpage>101</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">28861484</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0014"><string-name><surname>Mazur</surname>, <given-names>A.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Characterization of human hepatic and extrahepatic UDP‐glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids</article-title>. <source>Drug Metab. Dispos.</source><volume>37</volume>, <fpage>1496</fpage>–<lpage>1504</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19339377</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0015"><string-name><surname>Roden</surname>, <given-names>D.M.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Pharmacogenomics</article-title>. <source>Lancet</source><volume>394</volume>, <fpage>521</fpage>–<lpage>532</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31395440</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0016"><string-name><surname>Berger</surname>, <given-names>S.I.</given-names></string-name> &amp; <string-name><surname>Iyengar</surname>, <given-names>R.</given-names></string-name>
<article-title>Role of systems pharmacology in understanding drug adverse events</article-title>. <source>Wiley Interdiscip. Rev. Syst. Biol. Med.</source>
<volume>3</volume>, <fpage>129</fpage>–<lpage>135</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">20803507</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0017"><string-name><surname>Arbitrio</surname>, <given-names>M.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine</article-title>. <source>Oncotarget</source><volume>7</volume>, <fpage>54028</fpage>–<lpage>54050</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27304055</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0018"><string-name><surname>Ward</surname>, <given-names>L.D.</given-names></string-name> &amp; <string-name><surname>Kellis</surname>, <given-names>M.</given-names></string-name>
<article-title>HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants</article-title>. <source>Nucleic Acids Res.</source>
<volume>40</volume>, <fpage>D930</fpage>–<lpage>D934</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22064851</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0019"><string-name><surname>Gaston</surname>, <given-names>T.E.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Drug‐drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open‐label Expanded Access Program</article-title>. <source>Epilepsy Behav.</source><volume>98</volume>, <fpage>201</fpage>–<lpage>206</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31382177</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0020"><string-name><surname>Patsalos</surname>, <given-names>P.N.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs</article-title>. <source>Epilepsia</source><volume>61</volume>, <fpage>1854</fpage>–<lpage>1868</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32918835</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0021"><string-name><surname>Gaston</surname>, <given-names>T.E.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Interactions between cannabidiol and commonly used antiepileptic drugs</article-title>. <source>Epilepsia</source><volume>58</volume>, <fpage>1586</fpage>–<lpage>1592</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28782097</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0022"><string-name><surname>Sham</surname>, <given-names>P.C.</given-names></string-name> &amp; <string-name><surname>Purcell</surname>, <given-names>S.M.</given-names></string-name>
<article-title>Statistical power and significance testing in large‐scale genetic studies</article-title>. <source>Nat. Rev. Genet.</source>
<volume>15</volume>, <fpage>335</fpage>–<lpage>346</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24739678</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0023"><string-name><surname>Gaston</surname>, <given-names>T.E.</given-names></string-name> &amp; <string-name><surname>Friedman</surname>, <given-names>D.</given-names></string-name>
<article-title>Pharmacology of cannabinoids in the treatment of epilepsy</article-title>. <source>Epilepsy Behav.</source>
<volume>70</volume>, <fpage>313</fpage>–<lpage>318</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28087250</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0024"><string-name><surname>Ramasamy</surname>, <given-names>A.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Genetic variability in the regulation of gene expression in ten regions of the human brain</article-title>. <source>Nat. Neurosci.</source><volume>17</volume>, <fpage>1418</fpage>–<lpage>1428</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25174004</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0025"><string-name><surname>Okamura</surname>, <given-names>Y.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>COXPRESdb in 2015: coexpression database for animal species by DNA‐microarray and RNAseq‐based expression data with multiple quality assessment systems</article-title>. <source>Nucleic Acids Res.</source><volume>43</volume>, <fpage>D82</fpage>–<lpage>D86</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25392420</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0026"><string-name><surname>Messeguer</surname>, <given-names>X.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>PROMO: detection of known transcription regulatory elements using species‐tailored searches</article-title>. <source>Bioinformatics</source><volume>18</volume>, <fpage>333</fpage>–<lpage>334</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">11847087</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0027"><string-name><surname>Stelzer</surname>, <given-names>G.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>The GeneCards Suite: from gene data mining to disease genome sequence analyses</article-title>. <source>Curr. Protoc. Bioinformat.</source><volume>54</volume>, <fpage>1.30.1‐1.30.33</fpage> (<year>2016</year>).</mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0028"><string-name><surname>Thorn</surname>, <given-names>C.F.</given-names></string-name>, <string-name><surname>Aklillu</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Klein</surname>, <given-names>T.E.</given-names></string-name> &amp; <string-name><surname>Altman</surname>, <given-names>R.B.</given-names></string-name>
<article-title>PharmGKB summary: very important pharmacogene information for CYP1A2</article-title>. <source>Pharmacogenet. Genomics</source>
<volume>22</volume>, <fpage>73</fpage>–<lpage>77</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">21989077</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0029"><string-name><surname>Bangsow</surname>, <given-names>T.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>The epithelial membrane protein 1 is a novel tight junction protein of the blood‐brain barrier</article-title>. <source>J. Cereb. Blood Flow. Metab.</source><volume>28</volume>, <fpage>1249</fpage>–<lpage>1260</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18382472</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0030"><string-name><surname>Boyle</surname>, <given-names>A.P.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Annotation of functional variation in personal genomes using RegulomeDB</article-title>. <source>Genome Res.</source><volume>22</volume>, <fpage>1790</fpage>–<lpage>1797</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22955989</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0031"><string-name><surname>Silvestro</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Schepici</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Bramanti</surname>, <given-names>P.</given-names></string-name> &amp; <string-name><surname>Mazzon</surname>, <given-names>E.</given-names></string-name>
<article-title>Molecular targets of cannabidiol in experimental models of neurological disease</article-title>. <source>Molecules</source>
<volume>25</volume>, <fpage>5186</fpage> (<year>2020</year>).</mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0032"><string-name><surname>Jurecka</surname>, <given-names>A.</given-names></string-name><article-title>Inborn errors of purine and pyrimidine metabolism</article-title>. <source>J. Inherit. Metab. Dis.</source><volume>32</volume>, <fpage>247</fpage>–<lpage>263</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19291420</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0033"><string-name><surname>Caudle</surname>, <given-names>K.E.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing</article-title>. <source>Clin. Pharmacol. Ther.</source><volume>94</volume>, <fpage>640</fpage>–<lpage>645</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23988873</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0034"><string-name><surname>Melrose</surname>, <given-names>J.</given-names></string-name><article-title>Keratan sulfate (KS)‐proteoglycans and neuronal regulation in health and disease: the importance of KS‐glycodynamics and interactive capability with neuroregulatory ligands</article-title>. <source>J. Neurochem.</source><volume>149</volume>, <fpage>170</fpage>–<lpage>194</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30578672</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0035"><string-name><surname>Miller</surname>, <given-names>G.M.</given-names></string-name> &amp; <string-name><surname>Hsieh‐Wilson</surname>, <given-names>L.C.</given-names></string-name>
<article-title>Sugar‐dependent modulation of neuronal development, regeneration, and plasticity by chondroitin sulfate proteoglycans</article-title>. <source>Exp. Neurol.</source>
<volume>274</volume>, <fpage>115</fpage>–<lpage>125</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26315937</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0036"><string-name><surname>Li</surname>, <given-names>X.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>CHST1 and CHST2 sulfotransferase expression by vascular endothelial cells regulates shear‐resistant leukocyte rolling via L‐selectin</article-title>. <source>J. Leukoc. Biol.</source><volume>69</volume>, <fpage>565</fpage>–<lpage>574</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11310842</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0037"><string-name><surname>Smith</surname>, <given-names>P.D.</given-names></string-name>, <string-name><surname>Coulson‐Thomas</surname>, <given-names>V.J.</given-names></string-name>, <string-name><surname>Foscarin</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Kwok</surname>, <given-names>J.C.</given-names></string-name> &amp; <string-name><surname>Fawcett</surname>, <given-names>J.W.</given-names></string-name>
<article-title>"GAG‐ing with the neuron": The role of glycosaminoglycan patterning in the central nervous system</article-title>. <source>Exp. Neurol.</source>
<volume>274</volume>, <fpage>100</fpage>–<lpage>114</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26277685</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0038"><string-name><surname>Rae</surname>, <given-names>C.D.</given-names></string-name> &amp; <string-name><surname>Williams</surname>, <given-names>S.R.</given-names></string-name>
<article-title>Glutathione in the human brain: Review of its roles and measurement by magnetic resonance spectroscopy</article-title>. <source>Anal. Biochem.</source>
<volume>529</volume>, <fpage>127</fpage>–<lpage>143</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28034792</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0039"><string-name><surname>Atalay</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Jarocka‐Karpowicz</surname>, <given-names>I.</given-names></string-name> &amp; <string-name><surname>Skrzydlewska</surname>, <given-names>E.</given-names></string-name>
<article-title>Antioxidative and anti‐inflammatory properties of cannabidiol</article-title>. <source>Antioxidants (Basel)</source>
<volume>9</volume>, <fpage>21</fpage> (<year>2019</year>).</mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0040"><string-name><surname>Grant</surname>, <given-names>S.M.</given-names></string-name> &amp; <string-name><surname>DeMorrow</surname>, <given-names>S.</given-names></string-name>
<article-title>Bile acid signaling in neurodegenerative and neurological disorders</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>21</volume>, <fpage>5982</fpage> (<year>2020</year>).</mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0041"><string-name><surname>Edmondson</surname>, <given-names>A.C.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Dense genotyping of candidate gene loci identifies variants associated with high‐density lipoprotein cholesterol</article-title>. <source>Circ. Cardiovasc. Genet.</source><volume>4</volume>, <fpage>145</fpage>–<lpage>155</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21303902</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0042"><string-name><surname>Couvert</surname>, <given-names>P.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL‐lowering response to fluvastatin therapy</article-title>. <source>Pharmacogenomics</source><volume>9</volume>, <fpage>1217</fpage>–<lpage>1227</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18781850</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0043"><string-name><surname>Ma</surname>, <given-names>W.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Catechol estrogens stimulate insulin secretion in pancreatic β‐cells via activation of the transient receptor potential A1 (TRPA1) channel</article-title>. <source>J. Biol. Chem.</source><volume>294</volume>, <fpage>2935</fpage>–<lpage>2946</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30587572</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0044"><string-name><surname>Al‐Rubae'i</surname>, <given-names>S.H.</given-names></string-name>, <string-name><surname>Naji</surname>, <given-names>T.S.</given-names></string-name> &amp; <string-name><surname>Turki</surname>, <given-names>K.M.</given-names></string-name>
<article-title>Common variation of the CYP17 gene in Iraqi women with endometriosis disease</article-title>. <source>Genomics Data</source>
<volume>11</volume>, <fpage>55</fpage>–<lpage>59</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">27981034</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0045"><string-name><surname>Kino</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Su</surname>, <given-names>Y.A.</given-names></string-name> &amp; <string-name><surname>Chrousos</surname>, <given-names>G.P.</given-names></string-name>
<article-title>Human glucocorticoid receptor isoform beta: recent understanding of its potential implications in physiology and pathophysiology</article-title>. <source>Cell. Mol. Life Sci.</source>
<volume>66</volume>, <fpage>3435</fpage>–<lpage>3448</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19633971</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0046"><string-name><surname>Morales</surname>, <given-names>P.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Therapeutic exploitation of GPR18: beyond the cannabinoids?</article-title><source>J. Med. Chem.</source><volume>63</volume>, <fpage>14216</fpage>–<lpage>14227</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32914978</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0047"><string-name><surname>Niesler</surname>, <given-names>B.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Characterization of the novel human serotonin receptor subunits 5‐HT3C,5‐HT3D, and 5‐HT3E</article-title>. <source>Mol. Pharmacol.</source><volume>72</volume>, <fpage>8</fpage>–<lpage>17</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17392525</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0048"><string-name><surname>Fakhfouri</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Rahimian</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Dyhrfjeld‐Johnsen</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zirak</surname>, <given-names>M.R.</given-names></string-name> &amp; <string-name><surname>Beaulieu</surname>, <given-names>J.M.</given-names></string-name>
<article-title>5‐HT3 receptor antagonists in neurologic and neuropsychiatric disorders: the iceberg still lies beneath the surface</article-title>. <source>Pharmacol. Rev.</source>
<volume>71</volume>, <fpage>383</fpage>–<lpage>412</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31243157</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0049">
                <label>49</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0049"><string-name><surname>Civelli</surname>, <given-names>O.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>G protein‐coupled receptor deorphanizations</article-title>. <source>Annu. Rev. Pharmacol. Toxicol.</source><volume>53</volume>, <fpage>127</fpage>–<lpage>146</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23020293</pub-id></mixed-citation>
              </ref>
              <ref id="cpt2408-bib-0050">
                <label>50</label>
                <mixed-citation publication-type="journal" id="cpt2408-cit-0050"><string-name><surname>Calver</surname>, <given-names>A.R.</given-names></string-name><italic toggle="yes">et al</italic>. <article-title>Molecular cloning and characterisation of a novel GABAB‐related G‐protein coupled receptor</article-title>. <source>Brain Res. Mol. Brain Res.</source><volume>110</volume>, <fpage>305</fpage>–<lpage>317</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12591167</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
